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 12 (S)-HPETE 12(S)-hydroperoxyeicosa-5Z, 8Z, 10E, 14Z-tetraenoic acid 
 2-AG  2-arachidonoyl glycerol  
 AA arachidonic acid 
 AgaIVA w-agatoxin IVA 
 AM acetocy-methyl 
 AMPA a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid  
 anandamide  arachidonoyl ethanolamide  
 [Ca2+]i intracellular Ca2+ concentration  
 CaMK Ca2+/calmodulin-dependent protein kinase 
 CNS central nervus system 
 cPLA2a cytosolic PLA2a 
 DAG diacylglycerol 
 DMEM  Dulbecco’s modified Eagle’s medium  
 ER endoplasmic reticulum  
 ERK extracellular signal-regulated kinase  
 FBS  fetal bovine serum  
 GalT b-1,4-galactosyltransferase 
 GFP green fluorescent protein 
 GRIP glutamate receptor interacting protein 
 HBSS Hank’s balanced salt solution  
 IP3 inositol 1,4,5-trisphosphate; PKC, protein kinase C 
 LTD long-term depression  
 MAP mitogen-activated protein 
 MEK MAP kinase kinase  
 mGlu metabotropic glutamate 
 OGB-1 oregon green 488 BAPTA-1 
 PICK1 protein interacting with C kinase 1 
 PLA2 phospholipase A2  
 PTX  pertussis toxin  
 PY phosphotyrosine 
 RFP red fluorescent protein 
 TBS Tris-buffered saline
 
 
 
  
General Remarks 
  
In the central nervus system (CNS), arachidonic acid and the metabolites including 
prostaglandin, leukotrien, platelet activating factor, and lysophosphatidic acid have been 
suggested to exert a variety of neuromodulatory actions such as fever generation, 
sleep-wakefulness regulation, and induction of synaptic plasticity in physiological conditions, as 
well as promotion of neuronal death after cerebral ischemia in pathological conditions.  The 
initial step of the arachidonic acid cascade is regulated by action of cytosolic phospholipase A2a 
(cPLA2a).  In fact, ischemic brain injury are markedly reduced in cPLA2a knockout mice 
compared with that in wild-type mice.  cPLA2a hydrolyzes the acyl group from the sn-2 
position of glycerophospholipids, generating arachidonic acids and lysophospholipids.  
cPLA2a is distributed in most regions of the brain and is predominantly localized in neurons.  
In non-neuronal cells, this enzyme activity is strictly regulated by two distinct cellular 
signalings: Ca2+-dependent translocation and phosphorylation.  To raise intracellular Ca2+ 
concentration ([Ca2+]i) resulted in the translocation of cPLA2a from cytosol to perinuclear 
membranes such as neuclear, endoplasmic reticulum, and Golgi apparatus.  This translocation 
makes cPLA2a assess phospholipids as a substrate.  cPLA2a is phosphorylated by kinase such 
as mitogen-activated protein kinase and Ca2+/calmodulin-dependent protein kinase II, leading to 
enhance the enzyme activity.  However the detail mechanisms for the activation in neuronal 
cells is unknown.  Therefore, we examined the subcellular distribution and phosphorylation 
state of cPLA2a in cultured Purkinje neurons and PC12 cells, a neuronal model cell line in 
Chapter I and II respectively.  To understand this issue would help to acquire clinical benefits 
and to resolve brain function and process of memory formation.   
 In Chapter I, cPLA2a has been proposed to be involved in the induction of long-term 
depression (LTD), which is a form of synaptic plasticity in cerebellar Purkinje cells.  We 
investigated the role of cPLA2a in the molecular mechanism underlying the LTD.  LTD is 
synaptic depression between paraller fiber and Purkinje cells by persistent internalization of 
AMPA receptors.  We indicated that LTD inducing stimulation could cause full activation of 
cPLA2a in cultured Purkije cells, and that arachidonic acid released by cPLA2a contributed to 
long-term maintenance of surface AMPA receptor internalization. 
 In Chapter II, We show that intracellular signaling from activation of endocannabinoid 
receptor to release of arachidonic acid by cPLA2a in PC12.  Endocannabinoids consist mainly 
of marijuana.  The cannabinoid receptors are classified under the G-protein coupled receptor 
superfamily: CB1 and CB2 receptors.  The formers are expressed mainly in the brain, but also 
in the lungs, liver and kidneys and the latters are mainly expressed in the immune system and in 
hematopoietic cells.  In the CNS, CB1 receptors show the localization in presynaptic terminals 
  
and tightly regulate the probability of neurotransmitter release.  The endocannabinoid signals 
are thought to be important in synaptic plasticity.  Our laboratory had previously showed that 
treatment of CB1 receptor ligands caused the elevation of arachidonic acid release in PC12 cells.  
Now we investigated further cellular signaling following activation of CB1 receptor for 
cPLA2a-dependent arachidonic acid release.  
 
  
 
 
 
 
 
Chapter I 
 
 
 
Glutamate-induced translocations to the somatic and dendritic Golgi compartments and 
phosphorylation of cytosolic phospholipase A2a regulates AMPA receptor surface expression 
in cerebellar Purkinje cells
  
Introduction 
 
Long-term depression (LTD) of synaptic transmission at excitatory parallel 
fiber-Purkinje cell synapses in the cerebellum is induced when parallel fiber and climbing fiber 
inputs to a Purkinje cell are repeatedly coactivated, which contributes to certain forms of motor 
learning and coordination (Derkach et al., 2007; Ito, 2001; Steinberg et al., 2006; Tanaka et al., 
2007).  The induction of LTD is triggered by a large postsynaptic Ca2+ influx through 
voltage-sensitive Ca2+ channels and by the activation of two groups of glutamate receptors: 
ionotropic a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors and 
type-I G protein-coupled metabotropic glutamate (mGlu) receptors.  Over the past two decades, 
some of the signal transduction mechanisms controlling the induction of this form of synaptic 
plasticity have been established (Evans, 2007; Ito, 2002).  Much evidence suggests that the 
depression of synaptic activity in parallel fiber-Purkinje cell synapses is primarily expressed 
through the activity-dependent removal of AMPA receptors containing the subunit GluR2 from 
the postsynaptic membrane of Purkinje cell dendrites (Derkach et al., 2007; Evans, 2007; 
Matsuda et al., 2000; Xia et al., 2000).  AMPA receptors form heterooligomeric complexes 
composed of the subunits GluR1–4, and GluR2/3 receptors are predominant in Purkinje cells.  
A number of signaling pathways converge on AMPA receptor trafficking to regulate the 
stabilization of AMPA receptor clusters at synapses and determine whether there is a net 
increase or decrease of synaptic AMPA receptors.  A large increase in dendritic Ca2+ due to the 
activation of climbing fibers, combined with production of inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol downstream of the type-I mGlu receptor, activates protein kinase C (PKC).  The 
removal of AMPA receptors during LTD correlates with phosphorylation of GluR2 at Ser880 in 
the carboxy-terminal by PKCa (Chung et al., 2003; Leitges et al., 2004).  Unphosphorylated 
GluR2 on the plasma membrane preferentially interacts with the PDZ domain-containing 
protein glutamate receptor interacting protein (GRIP), which favors the presence of the receptor 
at synapses.  After phosphorylation by PKCa, GluR2 dissociates from GRIP and binds protein 
interacting with C kinase 1 (PICK1), and this leads to a decrease in the number of synaptic 
AMPA receptors via clathrin-mediated endocytosis (Matsuda et al., 2000; Wang and Linden, 
2000).  
Although many other signaling molecules such as mitogen-activated protein (MAP) 
kinase (Endo and Launey, 2003a; Endo and Launey, 2003b; Kawasaki et al., 1999; Tatsukawa et 
al., 2006), Ca2+/calmodulin-dependent protein kinase (CaMK) II and IV (Ahn et al., 1999; 
Hansel et al., 2006), and NO synthase (Boxall and Garthwaite, 1996) are involved in the 
induction of cerebellar LTD, phospholipase A2 (PLA2) has obtained particular attention since 
there is substantial evidence that its product arachidonic acid serves as an intracellular 
  
messenger that modulates synaptic transmission (Kuroda et al., 2001; Linden, 1995; Massicotte, 
2000; Reynolds and Hartell, 2001).  First, arachidonic acid is produced in a variety of neuronal 
cell preparations in response to the activation of glutamate receptors under certain conditions 
(Stella et al., 1995), and the application of arachidonic acid to cerebellar slices depresses the 
synaptic current at parallel fibers to Purkinje cell synapses (Kovalchuk et al., 1994).  Second, 
inhibitors of PLA2 converted LTD to short-term depression, and this effect is compensated by 
exogenously applied arachidonic acid (Linden, 1995; Reynolds and Hartell, 2001).  Third, 
arachidonic acid or unsaturated fatty acids can produce a large, synergistic activation of PKC 
and consequent phosphorylation of its substrate proteins when present together with 
diacylglycerol and Ca2+ (Lopez-Nicolas et al., 2006; McPhail et al., 1984; O'Flaherty et al., 
2001).  In addition, roles for Ca2+-activated PLA2 and/or arachidonic acid in cerebellar LTD 
were assumed in a computational simulation based on a positive-feedback signal transduction 
cycle that includes Ca2+, PKC, Raf, MAP kinase kinase (MEK), extracellular signal-regulated 
kinase (ERK), Ca2+-dependent PLA2, and arachidonic acid (Kuroda et al., 2001; Tanaka et al., 
2007).  This model can reproduce the properties of Ca2+-triggered LTD through stable 
phosphorylation of GluR2 by sustained activation of PKC. 
Since the production of free arachidonic acid from membrane phospholipids is tightly 
controlled by PLA2 activity, elucidating the function and regulation of PLA2 involved in the 
mobilization of arachidonic acid in Purkinje cells is important to better understand the 
molecular mechanism underlying LTD.  PLA2 comprises a family of more than 20 isozymes 
and is classified into three main groups, cytosolic Ca2+-dependent (cPLA2), Ca2+-independent, 
and secretory.  Among these PLA2s, group IVA PLA2/cytosolic phospholipase A2a (cPLA2a) 
is abundant in Purkinje neurons (Kishimoto et al., 1999; Kuroda et al., 2001; Shirai and Ito, 
2004).  This enzyme preferentially catalyzes the hydrolysis of the sn-2 position of 
glycerophospholipids containing arachidonic acid, and its activation is regulated by an increase 
in the intracellular Ca2+ concentration ([Ca2+]i) and phosphorylation at serine residues (Ghosh et 
al., 2006; Kudo, 2004; Leslie, 1997).  In many non-neuronal cells, the binding of Ca2+ to an 
N-terminal C2 domain induces translocation of cPLA2a from the cytosol to perinuclear region 
including the Golgi apparatus, endoplasmic reticulum (ER), and nuclear membranes for 
accessing glycerophospholipid substrates (Evans et al., 2001; Hirabayashi et al., 1999).  Serine 
phosphorylation is mediated by ERK, CaMKII, and MAP kinase-interacting kinase Mnk1 
(Hefner et al., 2000; Kramer et al., 1996; Pavicevic et al., 2008; Sano et al., 2001).  Although 
cPLA2a has been shown to play physiological and pathophysiological roles in many tissues and 
cell types (Clark et al., 1995; Hirabayashi et al., 2004; Kita et al., 2006), the function of this 
enzyme in cerebellar plasticity has not been fully addressed.  Here, we have used live imaging 
and immunocytochemistry to monitor the translocation and phosphorylation of cPLA2a, 
  
mobilization of Ca2+, and surface expression of AMPA receptors in cultured cerebellar Purkinje 
cells.  Our results suggest that dynamic translocation of cPLA2a to the somatic and dendritic 
Golgi apparatus in Purkinje neurons is controlled by AMPA receptor-mediated Ca2+ influx 
through voltage-gated Ca2+ channels and that full activation of this enzyme and consequent 
liberation of arachidonic acid are required for the prolonged decrease in the synaptic surface 
expression of AMPA receptors, which may underscore the key regulatory role of cPLA2a in 
cerebellar LTD.  
 
 
 
 
 
  
Materials and Methods 
 
Cerebellar cultures.  Primary cerebellar cell cultures were prepared from neonatal ICR mice 
and Wistar rats (P0), as previously described (Okubo et al., 2001) with minor modifications.  
Briefly, the cerebellum was treated with the cell dispersion solution (Sumitomo Bakelite, Japan), 
and the dispersed cells were plated at a density of 2.0´105 cells/cm2 on glass bottom 35-mm 
dishes (f = 12 mm, Iwaki, Japan) coated with 0.01% poly-D-lysine (Sigma, St. Louis, MO, 
USA) and grown for 24 h at 37°C in neuronal culture medium (Sumilon Nerve Culture System, 
Sumitomo Bakelite) containing 10 mM HEPES, pH 7.4, under a humidified atmosphere 
containing 5% CO2.  Then, the medium was changed to Neurobasal A medium (Invitrogen, 
Carlsbad, CA) supplemented with B-27 (Invitrogen), 2 mM L-glutamate and 10 mM HEPES, 
pH 7.4.  Half of the medium was replaced every 5 days.  Cells cultured for 3–4 weeks were 
used for the experiments.  Animals were treated in accordance with the Guiding Principles for 
the Care and Use of Laboratory Animals approved by the Japanese Pharmacological Society and 
the experiments were approved by the Experimental Animal Committee at the authors’ 
institution.  
 
Immunocytochemistry.  For endogenous cPLA2a staining, cells were fixed with 4% 
paraformaldehyde for 10 min at room temperature, permeabilized with 0.1% Triton-X 100 for 
20 min, and blocked with 10% normal goat serum (Sigma).  The polyclonal anti-cPLA2a 
(Santa Cruz Biotech., Santa Cruz, CA, 1:100 dilution) and monoclonal anti-calbindin D (Sigma, 
1:1000) antibodies were revealed using Alexa Fluor 488- and Alexa Fluor 546-labeled 
secondary antibodies (Invitrogen), and neurons were imaged using an LSM510 Laser Scanning 
Microscope (Carl Zeiss, Germany).  For phosphorylated cPLA2a, cells were fixed with 4% 
paraformaldehyde in Tris-buffered saline (TBS), pH 7.4 for 10 min at room temperature, and 
treated with methanol for 10 min at –20°C.  Then, the preparations were blocked with 10% 
normal goat serum (DAKO, Germany) with 1% BSA in TBS.  For the staining of GluR2 on the 
cell surface, rat cerebellar cultures were prepared, since the anti-GluR2 antibody (a gift from Dr. 
Hirokazu Hirai, Gunma University, Japan) reacts with GluR2 from rats much greater than that 
from mice.  Although the immunoreactivity of mouse GluR2 was very weak, similar trends 
were also observed in mouse Purkinje cells.  Cells were fixed with 4% paraformaldehyde in 
PBS, and the preparations were blocked with 3% BSA without the permeabilization step.  
Antibodies to phospho-Ser505-cPLA2a (Cell Signaling, Beverly, MA, 1:200), calbindin D 
(1:1,000), and GluR2 (1:200) were used, followed by Alexa Fluor 488- and 546-conjugated 
secondary antibodies (Molecular Probes).  For endogenous PKCa staining, cells were fixed 
with 4% paraformadlegyde for 10 min at room temperature, permeablilized with methanol for10 
  
min at –20°C, and blocked with 1% goat serum, 1% BSA, and 0.3% Triton X-100 for 1 h at 
37°C.  The polyclonal anti-PKCa (Santa Cruz Biotech., 1:200 dilution) were revealed using 
Alexa Fluor 488-labeled secondary antibodies.  Fluorescent images were taken using a 
Fluoview 500 laser-scanning microscope IX60 equipped with a 60´ water-immersion objective 
(NA = 1.2), 488- and 543-nm laser lines for excitation, 515–540 nm band-pass and 560 nm 
long-pass filters for emission, or ZEISS Axiovert S100 with a 40´ objective (NA = 0.17).  
 
Recombinant Sindbis viral vectors.  The cDNA fragments encoding full-length human cPLA2a 
were inserted into the expression vector pEGFP-C1 (Clontech, Palo Alto, CA) to construct 
green fluorescent protein (GFP)-cPLA2a as previously described (Hirabayashi et al., 1999).  
The region coding for GFP was replaced by monomeric red fluorescent protein (RFP, a gift from 
Dr. Roger Tsien, University of California, San Diego) to obtain RFP-cPLA2a.  GFP-GalT, a 
Golgi marker encoding the N-terminal 82 residues of human b-1,4-galactosyltransferase (GalT), 
was constructed by modification of CFP-Golgi (Clontech).  The cDNA fragments encoding 
GFP, DsRed-Express (Clontech), GFP-cPLA2a, RFP-cPLA2a, GFP-GalT, and RFP-calreticulin, 
a marker for ER, were subcloned into the vector pSinRep5 (Invitrogen).  All constructs were 
confirmed by sequencing.  These vectors were linearized and subsequently transcribed in vitro 
into capped mRNA with the mMessage mMachine SP6 kit (Ambion, Austin, TX) according to 
the manufacturer’s instructions.  The RNA transcripts and the helper RNA from the DH(26S) 
cDNA template (Invitrogen) that encodes the genes for structural proteins of the Sindbis virus 
were electroporated into baby hamster kidney cells with a Gene Pulser II (Bio-Rad, Hercules, 
CA) in the presence of 1 mM RNasin (Promega, Madison, WI).  After 36–48 h of incubation in 
a-modified Eagle’s medium supplemented with 5% fetal bovine serum (FBS), the culture 
supernatant containing the infectious particles of replication-incompetent pseudovirus was 
harvested.  The viral particles were concentrated by centrifugation at 10,000´g for 1 h and 
preserved at –80°C until used.    
 
Live-cell confocal microscopy and Ca2+ imaging.  The infectious pseudovirions were diluted 
into the culture medium so that approximately 40–80% of cultured Purkinje cells were infected.  
The cerebellar cultures were incubated in this condition for 16–24 h at 37°C in the presence of 1 
mM tetrodotoxin (Wako, Osaka, Japan) to block spontaneous action potentials.  Sindbis virus 
did not cause any apparent toxicity in cerebellar neurons for at least 2 days.  The cultures were 
washed three times with Hank’s balanced salt solution (HBSS) containing 10 mM HEPES, pH 
7.4, and incubated in the same buffer for 30 min at 37°C in the presence of tetrodotoxin.  
Confocal microscopy was performed on a Fluoview 500 laser-scanning microscope IX60 
equipped with a 60´ water-immersion objective (NA = 1.2), 488 and 543 nm laser lines for 
  
excitation, 515–540 nm band-pass and 560 nm long-pass filters for emission, and an incubation 
chamber to keep the temperature constant at 37°C (Olympus, Tokyo, Japan).  Time-lapse 
sequences were recorded with Fluoview Tiempo, and fluorescence intensity was quantified 
using FluoView version 4.2 software.  For the imaging of [Ca2+]i, the cells were preloaded for 
45 min at 37°C with 6 mM Oregon Green 488 BAPTA-1 acetoxy methyl (OGB-1/AM, a 
green-emitting Ca2+-sensitive fluorescent probe, Invitrogen) in HBSS containing 0.1% BSA and 
10 mM HEPES, pH 7.4.   
 
Release of arachidonic acid.  The cerebellar cells were seeded onto 48-well plates at a density 
of 3´105 cells/well in the growth medium.  After a 3-week culture, the cells were labeled by 
overnight incubation with Neurobasal medium containing 0.05 mCi/well of [3H]arachidonic acid 
(Amersham, Buckinghamshire, UK), B-27 supplement, 0.1% BSA, and 10 mM HEPES, pH 7.4.  
The cells were washed three times with HBSS containing 0.1% BSA and 10 mM HEPES, pH 
7.4, and stimulated with the indicated reagents at 37°C in the same buffer.  The radioactivity of 
the supernatant and cell lysates (in 1% Triton X-100) was measured by liquid scintillation 
counting and the amount of radioactivity released into the supernatant was expressed as a 
percentage of the total amount incorporated (Hirabayashi et al., 1999). 
 
Reagents.  Glutamate and PMA [4b-phorbol 12-myristate 13-acetate] were obtained from 
Sigma (St Louis, MO).  AMPA, CNQX [6-cyano-7-nitroquinoxaline-2,3-dione disodium], 
ACPD [(1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid], and MCPG [(RS)-a-methyl-4- 
carboxyphenylglycine] were from Research Biochem. Int. (Natick, MA).  w-Agatoxin IVA was 
from PEPTIDE Institute (Osaka, Japan).  Pyrrophenone was kindly provided by Shionogi 
Pharm. Ltd. (Osaka, Japan).  U0126 was obtained from Calbiochem (San Diego, CA).  To 
prepare stock solutions, reagents other than CNQX were dissolved in distilled water, and CNQX 
was dissolved in dimethylsulfoxide.  Stock solutions of reagents were diluted with the buffer 
and then adjusted to pH 7.4.  Administration of glutamate receptor agonists was performed for 
10–15 s by gravity flow through a micropipette positioned beside the cells, which enabled a 
local application of the reagents to the targeted cells.  The administration rate was about 1 ml 
per sec.   
 
Data analysis.  Fluorescence data were processed with ImageJ 1.38 (National Institutes of 
Health) and expressed as DF/F0, i.e. as background-corrected increases in fluorescence (DF) 
divided by the pre-stimulus fluorescence (F0).  The highest value of DF/F0 in each trace was 
defined as the peak value.  Values are means ± s.e.m. from more than three independent 
experiments.  In the case of multiple comparisons, the significance of differences was 
  
determined using a one-way analysis of variance followed by the Bonferroni test.  For pairwise 
comparisons, the Student’s two-tailed t-test was used.  P values < 0.05 were considered 
significant. 
 
  
Results 
 
Glutamate stimulates cPLA2a  translocation to the somatic and dendritic Golgi apparatus in 
Purkinje cells 
We first examined the distribution of endogenous cPLA2a in cultured mouse 
cerebellar neurons by immunocytochemistry.  Although Purkinje cells could be readily 
identified by their unique morphology with prominent dendritic trees, and large and round soma, 
their identity was confirmed by immunofluorescent costaining for calbindin-D (28K), a marker 
of Purkinje cells (Celio, 1990).  Endogenous cPLA2a was present uniformly in both the soma 
and dendrites of calbindin D-positive Purkinje cells (Fig. 1), whereas significant 
immunoreactivity was only occasionally observed in the long extended axons.  
Immunostaining for cPLA2a was rather weak in other cell types.  The predominant distribution 
of cPLA2a in the soma and dendrites in Purkinje cells is consistent with a recent study using rat 
cerebellar slices (Shirai and Ito, 2004).  
To visualize the subcellular localization of cPLA2a in live Purkinje cells in response to 
glutamate, fluorescent tagged-cPLA2a (GFP-cPLA2a) was expressed in cultured cerebellar 
neurons by use of the Sindbis virus-based expression system.  The Sindbis viral vectors were 
used because of their preference for neurons over glial cells and high expression levels of 
exogenous recombinant genes (Ehrengruber et al., 1999).  In unstimulated Purkinje cells, 
GFP-cPLA2a was present uniformly in the soma and dendrites (Fig. 2A), which was similar to 
the distribution of endogenous cPLA2a.  The puff application of 30 mM glutamate to Purkinje 
cells induced a rapid redistribution of GFP-cPLA2a to a perinuclear convoluted structure in the 
soma and to discrete intracellular regions of dendritic shafts (Fig. 2A).  The sites of 
GFP-cPLA2a translocation in dendrites could be clearly visualized in the ratio image showing 
relative fluorescence intensity (DF/F0) (Fig. 2B).  The time course of DF/F0 in the most distal 
spiny dendrites exhibited a peak within a few seconds after the addition of glutamate, followed 
by a rapid decline (Figs. 2B, C).  A concomitant transient decrease in fluorescence in the 
adjacent distal spine may suggest the relocation of cPLA2a from spines to dendrites.  The 
values of DF/F0 at the dendritic branch points and at the target sites in the proximal dendrites 
and soma rose and fell with slower kinetics, depending on the distance from the soma (Fig. 2C).  
When cPLA2a was fused with monomeric RFP, the redistribution of RFP-cPLA2a in response 
to glutamate was essentially the same as that of GFP-cPLA2a (Fig. 4).  In contrast to these 
chimeric proteins, unconjugated GFP, RFP, and DsRed were present homogenously in the soma 
and dendrites of Purkinje cells, and their distribution was not affected by the application of 
glutamate (Figs. 2A, 3), indicating specific targeting of cPLA2a in response to glutamate. 
  To specify the site of cPLA2a translocation after the stimulation with glutamate, we 
  
compared the localization of cPLA2a to that of GalT, a well-characterized resident Golgi 
enzyme, tagged with GFP (GFP-GalT).  The convoluted and discrete distribution of 
RFP-cPLA2a in the cell soma and dendrites, respectively, after glutamate application showed a 
marked colocalization with GFP-GalT (Fig. 4).  In contrast, no significant colocalization of 
GFP-cPLA2a and RFP-calreticulin, a marker for ER, was observed in either the soma or 
dendrites of Purkinje cells treated with glutamate (data not shown).  These data indicate that 
glutamate stimulates cPLA2a translocation from the cytosol to the somatic and dendritic Golgi 
apparatus in Purkinje cells. 
 
AMPA receptor activation and Ca2+ influx through P-type Ca2+ channels regulate cPLA2a 
translocation  
Antagonists and agonists for glutamate receptors were used to determine which class 
of glutamate receptor is responsible for cPLA2a translocation.  When glutamate receptor 
antagonists were examined, the glutamate-induced translocation of GFP-cPLA2a to the 
dendritic and somatic Golgi was found to be completely inhibited in the presence of 30 mM 
CNQX, a selective AMPA receptor blocker (Figs. 5A, B), but not by treatment with 1 mM 
MCPG, a non-selective antagonist for mGlu receptors (Fig. 5C).  Moreover, when AMPA, 
NMDA, and mGlu receptors were selectively stimulated with a local application of AMPA, 
NMDA, and ACPD, respectively, only AMPA induced the Golgi based-distribution of 
GFP-cPLA2a (Fig. 5D, E, and data not shown).  These results indicate that activation of 
AMPA receptors is not only necessary but also sufficient for cPLA2a translocation.  A 
comparison of peak values for DF/F0 in dendrites in response to the application of glutamate 
receptor agonists and antagonists confirmed that the translocation of cPLA2a can be largely 
attributed to the activation of AMPA receptors (Fig. 5I).  The translocation and activation of 
cPLA2a are exquisitely regulated by the amount and duration of increase in [Ca2+]i in many cell 
types (Clark et al., 1995; Hirabayashi et al., 1999; Hirabayashi et al., 2004; Leslie, 2004).  
Since both AMPA and mGlu receptors mediate the mobilization of [Ca2+]i in Purkinje cells, we 
investigated how cPLA2a translocation is synchronized with the agonist-induced responses.  
Purkinje cells expressing RFP-cPLA2a were loaded with OGB-1/AM for simultaneous imaging 
of the distribution of cPLA2a and change in [Ca2+]i.  When the same cells were treated with 30 
mM AMPA, a drastic increase in both [Ca2+]i and RFP-cPLA2a translocation occurred (Fig. 6A).  
This detailed simultaneous analysis revealed that the increase in [Ca2+]i induced by activation of 
AMPA receptors was mirrored by the translocation of cPLA2a (Fig. 6A).  The rise in [Ca2+]i in 
dendrites slightly preceded that in soma.  Similarly, the AMPA-induced translocation of 
cPLA2a in dendrites was also followed by a subtlely delayed translocation in soma.  In 
contrast, stimulation of mGlu receptors with 300 mM ACPD caused a small increase in [Ca2+]i in 
  
both the dendrites and soma without remarkable changes in the subcellular localization of 
RFP-cPLA2a (Fig. 6B).  The temporal correlation between the increase in Ca2+ and the 
translocation of cPLA2a suggest that cPLA2a   redistribution in Purkinje cells is regulated by 
the mobilization of Ca2+ evoked by the activation of AMPA receptors.   
The requirement for an influx of Ca2+ in triggering cPLA2a translocation was tested by 
chelating extracellular Ca2+ in the bathing medium and in the presence of a Ca2+ channel blocker.  
Application of 4 mM EGTA abolished the translocation of GFP-cPLA2a induced by AMPA (Fig. 
5F).  Because Purkinje cells consistently express high levels of the AMPA receptor GluR2 
subunits with low Ca2+ permeability (Tempia et al., 1996), the pathway for AMPA-triggered 
Ca2+ influx is mainly through the P-type voltage-dependent Ca2+ channels that open in response 
to the depolarization resulting from the activation of AMPA receptors (Gruol et al., 1996).  
Indeed, the redistribution of GFP-cPLA2a elicited by application of AMPA was completely 
suppressed in the presence of 200 nM w-agatoxin IVA, a P-type voltage-gated Ca2+ channel 
blocker (Fig. 5G).  These observations indicate that the influx of Ca2+ from the extracellular 
space through the P-type voltage-gated Ca2+ channels is required for the AMPA-stimulated 
translocation of cPLA2a.  Furthermore, depolarization of Purkinje cells with high potassium 
(50 mM KCl) induced the translocation of GFP-cPLA2a (Fig. 5H), suggesting that a large 
increase in [Ca2+]i, via depolarization-evoked Ca2+ entry, promotes cPLA2a translocation in 
Purkinje cells.   
 
Phosphorylation by PMA leads to full activation of cPLA2a 
In addition to the Ca2+-induced translocation from the cytosol to organelle membranes, 
phosphorylation at Ser residues is a key event for the optimal activation of cPLA2a 
(Hirabayashi et al., 2004; Leslie, 2004).  The phosphorylation of this enzyme in Purkinje cells 
was examined by staining with an antibody against cPLA2a phosphorylated at Ser505.  The 
application of glutamate, AMPA, ACPD, or AMPA plus ACPD had no measurable effect in 
dendrites (Fig. 7, and data not shown), suggesting that the simple stimulation of glutamate 
receptors is not sufficient to fully activate cPLA2a.  Since the simultaneous application of 
AMPA and PMA causes LTD of synaptic transmission in Purkinje cells (Ito, 2001; Matsuda et 
al., 2000; Xia et al., 2000), the effect of PMA on cPLA2a phosphorylation was investigated.  
Treatment with 200 nM of PMA alone or with AMPA induced marked phosphorylation of 
cPLA2a in proximal dendrites of Purkinje cells (Fig. 7).  This phosphorylation was maintained 
for at least 2 h following the PMA treatment (PMA, 502.4 ± 84.1%, n = 10; PMA + AMPA, 
407.9 ± 63.3%, n = 8, Fig. 8).  The phosphorylation of cPLA2a at Ser505 by PMA plus AMPA 
was completely suppressed in the presence of 10 mM U0126, a MEK inhibitor.  This suggests 
that the MEK-ERK pathway is involved in the PMA-induced phosphorylation of cPLA2a in 
  
Purkinje cells.  Treatment with PMA alone did not cause cPLA2a translocation or a change in 
Ca2+ in Purkinje cells (Fig. 9), as previously shown in different cell types (Shimizu et al., 2004).  
We then examined the impact of cPLA2a phosphorylation on the enzymatic activity.  
In cerebellar cells prelabeled by incubation with [3H]arachidonic acid, co-stimulation with 
AMPA and PMA produced a significant increase in radioactivity in culture supernatants, taking 
only a small portion of Purkinje cells in the cultures into consideration (Fig. 10).  This 
elevation was abolished by pretreatment of the cells with 10 mM pyrrophenone, a potent and 
selective inhibitor of cPLA2a (Fig. 10).  These results suggest that endogenous cPLA2a is 
functional and activated to release arachidonic acid by the combination of AMPA and PMA.  
In contrast to the stimulatory effect of AMPA and PMA, neither AMPA, ACPD, nor PMA alone 
had significant effects on arachidonic acid liberation, indicating that full activation of 
cPLA2a in Purkinje cells requires its phosphorylation induced by PMA treatment in addition to 
its Ca2+-mediated translocation evoked by the stimulation of AMPA receptors. 
 
cPLA2a and arachidonic acid regulate prolonged internalization of GluR2  
To explore the functional implication of cPLA2a activation in AMPA receptor 
trafficking within Purkinje cells, we assessed the distribution of AMPA receptors by 
immunostaining with an anti-GluR2 N-terminal antibody in nonpermeabilized conditions.  
Cerebellar LTD has been shown to be expressed solely as a reduction in the number of synaptic 
AMPA receptors via clathrin-mediated endocytosis without a change in the properties of the 
receptor such as conductance and kinetics (Leitges et al., 2004; Linden, 2001).  Brief exposure 
of Purkinje cells to AMPA (30 mM, 1 min) in the presence of PMA (200 nM, 20 min) led to a 
sustained reduction of surface GluR2 intensity in the dendrites for at least 2 h after removal of 
the reagents (Figs. 11A, B), as reported previously (Matsuda et al., 2000).  Treatment with 
AMPA alone for 1 min did not change the surface expression of GluR2 (data not shown).  
Although pretreatment with pyrrophenone did not affect the decrease of GluR2 at the cell 
surface induced by PMA and AMPA during the initial 10 min, it did block the prolonged loss of 
the receptor from the surface at 2 h (Fig. 11B).  These findings suggest that cPLA2a activation 
is necessary for the prolonged internalization of GluR2 induced by the activation of AMPA 
receptors and PKC, but not for the induction of the receptor endocytosis.  As a corollary to 
these experiments, we tested the effect of arachidonic acid on GluR2 distribution.  PMA alone 
caused a loss of surface GluR2 expression under our conditions as reported previously (Matsuda 
et al., 2000), but this reduction did not continue for 2 h after the removal of PMA (Figs. 11C, D).  
The application of 200 mM arachidonic acid in addition to PMA resulted in a prolonged 
decrease in surface GluR2 intensity at 2 h to a similar level caused by combined stimulation 
with PMA and AMPA (Fig. 11C).  This suggests that a transient application of arachidonic acid 
  
could substitute for the activation of AMPA to sustain the PMA-induced internalization of 
GluR2.  Taken together, our study suggests that the activation of cPLA2a and resultant release 
of arachidonic acid have a critical role in regulating AMPA receptor trafficking by inducing 
persistent loss of surface GluR2 expression, which may provide a basis for the LTD of synaptic 
transmission in Purkinje cells.  
 
The transient treatment of arachidonic acid enhanced translocation of 
endogenous PKCa from cytosol to plasma membranes 
We investigated how arachidonic acid released by cPLA2a regulated the prolongation 
of AMPA receptors internalization.  Treatment of arachidonic acid has been reported to cause 
translocation of conventional PKC isoforms including a, b, and g from cytosol to plasma 
membrane (Kashiwagi et al., 1999; Yagi et al., 2004).  Conventional PKC isoforms contain C1 
domain where is involved in the recruitment of proteins to the membrane.  Typically, C1 
domains bind PMA, diacylglycerol, or arachidonic acid that are necessary for membrane 
localization.   In Purkinje cells, treatment of arachidonic acid resulted in translocation of 
endogenous PKCa from cytosol to plasma membrane as well as PMA (Fig. 12), suggesting 
arachidonic acid released by cPLA2a may be able to translocate and activate conventional PKC 
isoforms expressed in Purkinje cells.   
  
Discussion 
 
  The questions addressed here were how the translocation and activation of cPLA2a are 
controlled by stimuli involved in inducing cerebellar LTD and what is the possible functional 
consequence of this activation during the process of cerebellar LTD.  We found that the AMPA 
receptor-mediated influx of Ca2+ (Figs. 5, 6) regulates a dynamic redistribution of cPLA2a to the 
somatic and dendritic Golgi structures (Figs. 2, 4) and the concomitant phosphorylation at 
Ser505 by ERK (Fig. 7) leads to activation of this enzyme to liberate arachidonic acid in 
Purkinje cells (Fig. 10).  Importantly, cPLA2a activity is required for the sustained decrease in 
surface GluR2 expression induced by AMPA and PMA but not necessary for the initial 
internalization of GluR2 (Figs. 11A, B).  The transient application of PMA and arachidonic 
acid causes a persistent reduction in the amount of GluR2 at the cell surface (Figs. 11C, D), 
suggesting a pivotal role for cPLA2a and arachidonic acid in AMPA receptor trafficking.  The 
treatment of arachidonic acid resulted in translocation of endogenous PKCa from cytosol to 
plasma membranes (Fig. 12), which causes an activation of PKCa in cells.  Arachidonic acid 
released by cPLA2a in Purkinje cells may be a necessary component for prolongation of AMPA 
receptors internalization by sustained activation of PKCa. 
 
cPLA2a translocation to the somatic and dendritic Golgi apparatus 
 The translocation of cPLA2a to the dendritic Golgi structures in response to the 
activation of AMPA receptors (Fig. 4) strongly supports the localized production of arachidonic 
acid near postsynaptic compartments.  Previous studies have shown that many neurons possess 
both somatic Golgi and discrete, discontinuous Golgi-type structures located in dendrites 
(Horton and Ehlers, 2003).  The distribution of GFP-GalT in the dendrites in our study was in 
accord with the results of immunocytochemistry and live-cell confocal imaging to identify the 
Golgi apparatus in neuronal dendrites (Horton and Ehlers, 2003).  Although dendritic spines in 
most neurons contain organelles such as the smooth ER and stack-like structures that resemble 
the Golgi apparatus, called the spine apparatus (Job and Eberwine, 2001), no spine apparatus is 
present in Purkinje cells (Spacek, 1985).  Indeed, GFP-cPLA2a fluorescence in dendritic 
spines showed a rapid decrease upon stimulation with glutamate (Fig. 2C).  Thus, the target 
sites for cPLA2a in response to the stimulation of AMPA receptors are consistent with these 
characteristic features of Golgi structures in Purkinje neurons.   
 The temporal correlation between the increase in Ca2+ and cPLA2a translocation after 
activation of AMPA receptors (Fig. 6) and the requirement for Ca2+ influx in triggering this 
translocation (Figs. 5F, G) indicate that the Ca2+ signal is a critical determinant for regulating 
subcellular distribution of cPLA2a in stimulated Purkinje cells.  A role for Ca2+ binding to the 
  
C2 domain of cPLA2a as an electrostatic switch has been proposed by previous studies (Murray 
and Honig, 2002).  Ca2+ binding decreases the polarity on the surface of the C2 domain by 
neutralizing negative charges and promotes penetration of the hydrophobic region at one end of 
the domain into the membrane interior.  In contrast, phosphorylation of cPLA2a is required for 
increasing its intrinsic enzymatic activity rather than promoting translocation of this protein to 
membranes because the rate of membrane translocation is indistinguishable between wild-type 
cPLA2a and the S505A mutant in stimulated non-neuronal cells (Ghosh et al., 2006; 
Hirabayashi and Shimizu, 2000; Schievella et al., 1995). One report, however indicates that 
Ser505 phosphorylation improves the affinity of cPLA2a for the membrane at submicromolar 
Ca2+ (Das et al., 2003).  The promotion of cPLA2a phosphorylation by treatment with PMA 
produced no detectable alternation in AMPA-induced translocation of cPLA2a in Purkinje cells 
in our settings (Fig. 9).  Several other factors such as anionic phospholipids and cytoskeletal 
proteins may involve the translocation of cPLA2a. (Cybulsky et al., 2004; Fatima et al., 2005; 
Ghosh et al., 2006; Hirabayashi et al., 2004; Mosior et al., 1998; Subramanian et al., 2007).  
The interaction between cPLA2a and actin is especially interesting because actin polymerization 
is suggested to be involved in the surface expression of AMPA receptors in Purkinje cells 
(Tatsukawa et al., 2006). 
 
Role of cPLA2a in regulating surface expression of AMPA receptors 
 The inhibition of cPLA2a activity shortened the duration of decrease in surface GluR2 
expression triggered by the transient application of AMPA and PMA (Fig. 11B).  This indicates 
that cPLA2a activation and the resultant release of arachidonic acid regulate the recycling rather 
than internalization of GluR2.  The number of synaptic AMPA receptors is determined by the 
balance between insertion and removal of receptors at the postsynaptic site (Derkach et al., 
2007; Jörntell and Hansel, 2006; Tatsukawa et al., 2006).  These processes are highly dynamic 
and tightly regulated, likely involving exocytosis, endocytosis, and lateral diffusion in the 
plasma membrane.  Following clathrin-mediated endocytosis, the endocytosed AMPA 
receptors can be sorted into early endosomal compartments and then either recycled back to the 
plasma membrane or recruited to the lysosome for degradation, depending on the synaptic 
activity (Ehlers, 2000; Martin and Henley, 2004).  Thus, a likely explanation for the effect of 
cPLA2a inhibition on GluR2 surface expression is that cPLA2a activation switches AMPA 
receptors from the recycling pathway to the degradative pathway (Fig. 13).  In fact, PLA2 
activity has been proposed to play a role in endosome trafficking and lysosome activity in 
non-neuronal cells (Brown et al., 2003; Burlando et al., 2002; Mayorga et al., 1993).   
 
  
Signal transduction pathways involved in cerebellar LTD 
 A number of signaling pathways converge on AMPA receptor trafficking to regulate 
the synaptic expression of AMPA receptors.  The activation of type-I mGlu receptors at the 
parallel fiber-Purkinje cell synapse and large depolarization-induced increase in Ca2+ by 
climbing fiber inputs together evoke LTD (Linden, 1994).  As both inputs are required for LTD, 
signals from parallel and climbing fiber inputs to Purkinje cells should converge at some point 
in the molecular signaling cascade.  It is important to identify the molecules whose amount or 
activity changes more when a Purkinje cell receives two inputs within a certain time frame, 
because they may play a critical role in detection.  Our findings indicate that full activation of 
cPLA2a requires both the AMPA-induced Ca2+ influx through voltage-gated Ca2+ channels (Figs. 
5, 6) and the concomitant phosphorylation of this enzyme at Ser505 (Figs. 7, 8).  We propose 
that cPLA2a acts as a coincidence detector of signals required for the induction of LTD in 
Purkinje cells (Fig. 13).  The regulatory properties of cPLA2a are suited to such a role.  This 
proposal is further supported by the observation that a brief treatment of Purkinje cells with 
PMA and arachidonic acid promoted a prolonged reduction of synaptic GluR2 expression 
despite the absence of AMPA receptor stimulation and a large increase in Ca2+ (Figs. 11C, D). 
Inhibition of the phosphorylation of cPLA2a at Ser505 by MEK inhibitor U0126 
indicates the presence of the PKC-ERK-cPLA2a signaling cascade in Purkinje cells after 
stimulation with AMPA and PMA (Fig. 13).  Previous studies have proposed a computational 
model based on a positive-feedback signal transduction cycle that includes PKC, Raf, MEK, 
ERK, PLA2 and arachidonic acid, which is capable of reproducing the properties of 
Ca2+-triggered LTD through stable phosphorylation of AMPA receptors by sustained activation 
of PKC (Bhalla and Iyengar, 1999; Kuroda et al., 2001; Tanaka et al., 2007).  In this model, the 
initial activation of PKC due to the influx of Ca2+ and phospholipase Cb-mediated production of 
diacylglycerol results in activation of the Raf-MEK-ERK pathway.  ERK phosphorylates and 
activates cPLA2, and then the arachidonic acid produced by cPLA2 acts synergistically with 
diacylglycerol to reactivate PKC, establishing a positive feedback loop.  When the feedback 
loop is active, sustained activation of ERK and PKC can occur even after the extracellular signal 
is withdrawn.  Regarding the isoform of PKC that is responsible for LTD, PKC-a, -b and -g 
are all highly expressed in Purkinje cells, but strong evidence exists for PKCa, which, when 
knocked out in mice or knocked down in cultured Purkinje cells by RNA interference abolishes 
LTD which can only be rescued by PKCa and not by other isoforms (Leitges et al., 2004). 
 Although kinetic simulation supports this positive-feedback hypothesis and most of 
our data are not inconsistent with this predictive model, experimental data from some recent 
studies do not support the model.  For example, the conjunctional application of glutamate and 
depolarization pulses that induce LTD in cultured Purkinje cells triggered a transient 
  
translocation of PKCa to the plasma membrane (Tsuruno and Hirano, 2007).  This suggests 
that persistent activation of PKCa is not necessary for the expression of LTD.  In addition, the 
MEK inhibitor PD98059 suppressed declustering of GluR2/3 induced by PMA or the 
co-application of high potassium and glutamate without significant inhibition of 
phosphorylation of GluR2/3 at Ser880 (Endo and Launey, 2003a), implying that GluR2 
phosphorylation is not necessarily required for the prolonged internalization of AMPA receptors.  
Therefore, activation of PKCa and subsequent phosphorylation of GluR2 at Ser880 are both 
critical for the initial depression of synaptic efficacy, but their persistence may not be necessary 
for the maintenance of LTD.  In our proposed model, by controlling the degree of AMPA 
receptor recycling and/or by targeting internalized AMPA receptors for lysosomal degradation, 
the activation of cPLA2a and the release of arachidonic acid enable a sustained reduction in 
synaptic AMPA receptor expression independent of or parallel to the positive-feedback loop 
(Fig. 13). 
 There are several issues to be resolved in the future.  First, further research is needed 
to uncover the mechanism by which arachidonic acid regulates AMPA receptor trafficking.  It 
is also important to determine whether arachidonic acid is required to be transformed to its 
metabolites (prostaglandins, leukotrienes, and hydroxyeicosanoic acids).  For example, 
12(S)-hydroperoxyeicosa-5Z, 8Z, 10E, 14Z-tetraenoic acid (12(S)-HPETE), a 12-lipoxygenase 
metabolite of arachidonic acid, mediates mGlu receptor-dependent LTD at hippocampal 
CA3-CA1 synapses (Feinmark et al., 2003).  Second, it is necessary to confirm the role of 
cPLA2a in electrophysiology and examine the phenotype associated with cerebellar LTD in 
cPLA2a-deficent mice.  Finally, the apparently contradictory role of cPLA2a in synaptic 
plasticity remains to be explained (Ménard et al., 2005).  In the mouse hippocampus, inhibition 
of cPLA2 by caveolin-1-related peptide decreases the binding of AMPA to AMPA receptors 
containing GluR2, and may interfere with long-term potentiation in the mouse hippocampus 
(Gaudreault et al., 2004). 
   In summary, we have characterized the subcellular targeting and activation of cPLA2a 
in Purkinje cells in response to stimuli that induce cerebellar LTD.  The former is achieved by 
the activation of AMPA receptors that generate a large Ca2+ signal.  The target sites of cPLA2a 
are the dendritic and somatic Golgi structures.  However, this targeting is insufficient to 
stimulate enzymatic activity.  Additional phosphorylation at Ser505 is required to liberate 
arachidonic acid from membrane phospholipids.  A persistent decrease in the number of 
synaptic surface GluR2 AMPA receptors requires the activity of this enzyme.  The potent 
ability of arachidonic acid to modulate GluR2 trafficking through selective sorting of 
internalized GluR2 between recycling and degradative pathways might provide a basis for 
ensuring the induction of cerebellar LTD. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.  Endogenous expression of cPLA2a in Purkinje cells.  Immunofluorescent detection of 
the Purkinje marker calbindin D (A) and endogenous cPLA2a (B).  The merged image (C) 
shows colocalization of the two signals in yellow.  The immunostaining for cPLA2a in 
surrounding cells was rather weak.  Scale bar, 20 mm.  
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  Translocation of cPLA2a in living Purkinje cells in response to glutamate.  (A) An 
example of a Purkinje cell co-expressing GFP-cPLA2a and DsRed.  GFP-cPLA2a showed a 
uniform cytosolic distribution in unstimulated cells (upper panels, t = 0 s), whereas a marked 
translocation of GFP-cPLA2a to restricted sites was observed after stimulation with 30 mM 
glutamate (Glu, lower panels, t = 20 s).  DsRed was expressed to visualize the morphology of 
Purkinje cells simultaneously (inserts).  Note that all Z-series sections at 2-mm intervals were 
combined in two-dimensional XY images.  Rectangular regions corresponding to the dendrites 
and soma in the merged images were magnified with orthogonal sections viewing axial 
directions (ZX and ZY).  (B) Time-lapse images of GFP-cPLA2a fluorescence following the 
local application of a 30 mM glutamate solution (t = 1–5 s, indicated by the horizontal bar).  
Relative fluorescence intensity (DF/F0) is displayed according to a pseudocolor scale.  Scale 
bar, 20 mm.  In Panel C, traces represent the time course of DF/F0 measured in the indicated 
areas in Panel B.  Five small rectangles delimit the distal spiny dendrite (1), the distal spine (2), 
the dendritic branch point (3), the proximal main dendrite (4), and the soma (5), respectively.  
The peak time of DF/F0 depends on the distance from the soma.  Note that fluorescence is 
reduced gradually by bleaching.    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.  Localization of GFP at 30 s after application with glutamate.  Representative images 
of a Purkinje cell expressing GFP.  The distribution didn’t alter after stimulation with 30 mM 
glutamate.  scale bar, 20 mm 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.  Glutamate-induced translocation of cPLA2a to the somatic and dendritic Golgi 
apparatus.  (A) A whole Purkinje cell co-expressing RFP-cPLA2a and GFP-GalT (a maker of 
Golgi apparatus).  Scale bars, 20 mm.  (B) The target sites of RFP-cPLA2a in response to 30 
mM glutamate identified by subtraction analysis (left, the fluorescence image after glutamate 
addition was subtracted by the image before addition) colocalized with the Golgi marker 
GFP-GalT (middle) in the dendrites (upper panels) and soma (lower panels).  Colocalization is 
apparent as a yellow color in the merged image (right).  Scale bars, 5 mm. 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.  Regulation of cPLA2a translocation by AMPA receptors via P-type Ca2+ channels.  
(A–G) Time course of DF/F0 of GFP-cPLA2a in the dendritc (solid lines) and somatic Golgi 
(dashed lines) structures in Purkinje cells stimulated with a transient application of glutamate 
receptor agonists (A–C, 100 mM glutamate; D, 1 mM ACPD; E–G, 30 mM AMPA) in the 
absence or presence of glutamate receptor antagonists (B, 30 mM CNQX; C, 1 mM MCPG).  
Glutamate receptor agonists and 50 mM KCl (H) were administered by a local application near 
the Purkinje cells for the indicated period (horizontal solid bar).  Vehicle (A), antagonists (B 
and C), 5 mM EGTA (F), and 200 nM w-agatoxin IVA (AgaIVA, G) were bath-applied 5 min 
prior to the addition of agonists.  (I) Peak values of DF/F0 in the dendrites after stimulation.  
The values are means ± s.e.m. (n = 7–17).  *** P < 0.001 
  
 
 
Fig. 6.  Simultaneous observation of RFP-cPLA2a translocation and the Ca2+ response.  (A 
and B) Time-lapse images of RFP-cPLA2a (upper panels) and OGB-1 (lower panels) after 
agonist stimulation.  The same Purkinje cell was stimulated with 30 mM AMPA (A) or 300 mM 
ACPD (B).  The agonists were added at t = 0 s.  Scale bars, 20 mm. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7.  Phosphorylation of cPLA2a at Ser505.  (A) Immunocytochemistry with antibody to 
cPLA2a phosphorylated at Ser505 and to calbindin D.  Treatment with 200 nM PMA for 20 
min triggered marked phosphorylation of cPLA2a, whereas stimulation with glutamate receptor 
agonists alone (100 mM glutamate or 30 mM AMPA for 3 min) had little effect.  Pretreatment 
with 10 mM U0126 for 30 min completely blocked the phosphorylation of cPLA2a induced by 
the combination of PMA and AMPA.  Scale bar, 10 mm.  Quantification of experiments is 
shown in (B).  The average fluorescence intensity of phosphorylated cPLA2a in proximal 
dendrites after treatment with glutamate receptors agonist and/or PMA was calculated.  The 
values are means ± s.e.m. (n = 13–30 for each condition).  *** P < 0.001. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8.  Sustained phosphorylation of cPLA2a after PMA treatment.  (A) 
Immunocytochemistry with antibody to cPLA2a phosphorylated at Ser505 and to calbindin D.  
Purkinje cells were treatmented with 200 nM PMA for 20 min, and then stimulated for 3 min 
with vehicle or 30 mM AMPA. After washing, the cells were incubated for 2 hr at 37oC before 
fixation.  Scale bar, 10 mm.  (B) The fluorescence intensity of phosphorylated cPLA2a in 
proximal dendrites was measured.  The values are means ± s.e.m. (PMA, n = 10; PMA and 
AMPA, n = 8). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9.  Effect of PMA on AMPA-induced GFP-cPLA2a translocation. (A) Time-lapse images 
of GFP-cPLA2a fluorescence following the local application of a 30 mM AMPA solution (t = 
1–3 s) in the presence of 200 nM PMA, which was bath-applied 10 min prior to the addition of 
AMPA. DF/F0 of GFP-cPLA2a is displayed according to a pseudocolor scale.  Scale bar, 20 
mm.  (B) Time course of DF/F0 in the dendritc (solid lines) and somatic (dashed lines) Golgi 
structures measured in the indicated areas in Panel A.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10.  Pyrrophenone-sensitive release of arachidonic acid induced by AMPA/PMA.  
Cultured cerebellar cells were labeled with [3H]arachidonic acid, and preincubated with 200 nM 
PMA or vehicle for 20 min, and stimulated for 3 min with vehicle or glutamate receptor agonists 
(30 mM AMPA, 1 mM ACPD) by bath-application.  Pretreatment with 10 mM pyrrophenone 
(Pyrro) for 30 min completely blocked the increase in the release of arachidonic acid elicited by 
AMPA and PMA.  The values are means ± s.e.m. (n = 4–9).  *** P < 0.001. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11.  Effect of a cPLA2a inhibitor and arachidonic acid on surface GluR2 expression in 
Purkinje dendrites.  (A and B) Immunocytochemistry with polyclonal antibodies to the GluR2 
N-terminus revealed the surface expression of GluR2 receptors on dendrites with 
decombolution microscopy.  Cerebellar cultures were stimulated with 200 nM PMA for 20 min 
and 30 mM AMPA for 1 min in the absence or presense of 10 mM pyrrophenone and then 
washed with HBSS.  At the indicated time after the wash, the cells were processed for 
immunostaining.  Scale bar, 5 mm.  (B) Time course of the change in mean intensity of GluR2 
immunoreactivity in dendrites.  Data are shown as a percentage of control samples.  The 
cPLA2a inhibitor restored the prolonged reduction of postsynaptic GluR2 expression on 
Purkinje dendrites stimulated with PMA and AMPA.  The values were means ± s.e.m. (n = 
6–9).  (C and D) Purkinje cells were stimulated with 200 nM PMA for 20 min in the absence 
or presence of 200 mM arachidonic acid (AA), and then washed with HBSS.  At 120 min after 
the wash, the cells were processed for immunostaining of the expression of GluR2 on the 
dendrites.  Scale bar, 10 mm. The values are means ± s.e.m. (n = 6–9).  * P < 0.05, *** P < 
0.001. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12.  Translocation of endogenous PKCa after applicatin with PMA or arachidonic acid.   
Immunocytochemistry with polyclonal antibodies to PKCa revealed the translocation from 
cytosol to plasma membranes by PMA or arachidonic acid.  Cerebellar cultures were 
stimulated with 200 nM PMA or 200 mM arachidonic acid for 20 min and then washed with 
HBSS.  Lower panels show maginification images of dendrites indicated by rectangul in upper 
panels.  Scale bar, 50 mm. 
  
 
 
 
Fig. 13.  Model for a role of cPLA2a in LTD induction.  AMPA and PMA can mimic the 
stimuli that induce the depression of synaptic transmission in Purkinje cells.  LTD of synaptic 
activity is primarily expressed by the reduction in the number of postsynaptic AMPA receptors 
containing GluR2 subunit.  Phosphorylation of GluR2 at Ser880 by PKCa reduces its 
stabilizing interaction with GRIP and prefers PICK1 binding to GluR2 and subsequent 
internalization of the receptor to early endosomes.  Stimulation of AMPA receptors promotes a 
large Ca2+ influx through voltage-gated P-type Ca2+ channels, which in turn triggers cPLA2a 
translocation to the dendritic and somatic Golgi membranes.  Simultaneous phosphorylation of 
cPLA2a at Ser505 by ERK leads to an increase in its enzymatic activity.  Following the 
coincidence detection of the large Ca2+ signaling and activation of the PKC/MEK/ERK 
signaling pathway, cPLA2a is activated to produce free arachidonic acid.  This switches AMPA 
receptors from the recycling pathway to the degradative pathway by regulating endosome 
trafficking or lysosomal activity and ensures the persistent decrease in surface expression of 
AMPA receptors.  Regulatory molecules that provide a direct link between arachidonic acid 
and the sorting of internalized AMPA receptors remain to be identified.   
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Chapter 2 
 
 
 
 
Release of arachidonic acid by 2-arachidonoyl glycerol and HU 210 in PC12 cells; 
Roles of Src, phospholipase C and cytosolic phospholipase A2a
  
Introduction 
  
Cannabinoids, including the active components of marijuana, their synthetic analogs, 
and endogenous lipids with cannabinoid-like activity, exert most of their pharmacological and 
physiological effects by binding to specific G protein-coupled receptors, and two different 
cannabinoid (CB1 and CB2) receptors have been characterized and cloned (for review see Begg 
et al., 2005; Demuth and Molleman, 2006; Howlett, 2004; Piomelli, 2003).  Endogenous 
agonists for these receptors also exist; arachidonoyl ethanolamide (anandamide), 2-arachidonoyl 
glycerol (2-AG), and 2-arachidonyl glyceryl ether etc.  The cannabinoid CB1 receptor is 
distributed mainly in neuronal tissues including the brain, whereas the cannabinoid CB2 receptor 
is present in the immune system.  There is, in fact, growing evidence for the expression of 
cannabinoid CB2 receptors in neuronal tissues (Onaivi, 2006; Van Sickle et al., 2005) and 
cannabinoid CB1 receptors in non-neuronal tissues (Begg et al., 2005; Demuth and Molleman, 
2006; Howlett, 2004).  The activation of cannabinoid receptors causes the release of 
arachidonic acid and/or stimulation of phospholipase A2 (PLA2) (Howlett, 2004; Piomelli, 2003; 
Wartmann et al., 1995).  The activation of cannabinoid CB1 receptors causes the release of 
arachidonic acid in neuronal cells (Chan et al., 1998; Hunter and Burstein, 1997).  The 
activation of cannabinoid CB1 receptors in the brain regulates various neuronal functions such 
as hyperalgesia, behavioral changes, and neuronal death, and it is proposed that the 
PLA2-cyclooxygenase-prostanoid-cascade mediates these neuronal functions (Ates et al., 2003; 
Chan et al., 1998; Yamaguchi et al., 2004).  It was reported that the arachidonic acid cascade 
mediates the role of the endocannabinoid system in the reinstatement of 
methamphetamine-seeking behavior (Anggadiredja et al., 2004).  Although several reports 
suggest the involvement of pertussis toxin-sensitive G proteins and extracellular ERK1/2 in the 
release of arachidonic acid induced by anandamide and/or the activation of cannabinoid 
receptors (Piomelli, 2003; Wartmann et al., 1995), the signaling mechanism for the release of 
arachidonic acid and/or activation of PLA2 has not been elucidated.  In addition, some of the 
cannabinoid effects may be derived from certain chemical properties of cannabinoid reagents 
and from the interaction with specific membrane receptors distinct from cannabinoid CB1 or 
CB2 receptors (Begg et al., 2005; Howlett, 2004).     
PC12 cells (a neuronal model cell line) are widely used as catecholamine-containing 
neurons.  Treatment with cannabinoids or agonists of cannabinoid receptors caused the 
pharmacological responses such as inhibition of noradrenaline release and activation of 
intracellular signaling pathways in PC12 cells (Molderings et al., 2002; Erlandsson et al., 2002; 
Esposito et al., 2006).  PC12 cells have been shown to express both cannabinoid CB1 receptor 
mRNA and protein, but not the cannabinoid CB2 receptor (Sarker and Maruyama, 2003; Zhang 
  
et al., 2007), although some reports suggest that the cells are not endowed with cannabinoid CB1 
receptors (Esposito et al., 2006; Molderings et al., 2002).  Previously, we reported that 
expression of the a type of cytosolic PLA2 (cPLA2a) is regulated by nerve growth factor in 
PC12 cells (Akiyama et al., 2004).  Thus, the PC12 cell line appears to be a useful model for 
studying the cannabinoid-induced release of arachidonic acid and/or activation of cPLA2a.  In 
the present study, we investigated the signaling mechanism behind the release of arachidonic 
acid stimulated by 2-AG and HU210 [D8-tetrahydrocannabinol dimethyl heptyl] in PC12 cells.  
The effect of 2-AG on the release of arachidonic acid in cultured cells from the mouse 
cerebellum was also examined.  
  
Materials and Methods 
 
Chemicals.  The following chemicals and reagents were used: 
[5,6,8,9,11,12,14,15-3H]arachidonic acid (215 Ci/mmol, 7.96 TBq/mmol, Amersham, 
Buckinghamshire, UK), PD098059 [2-(2-amino-3.methoxyphenyl)-4H-1-benzopyran-4-one], 
wortmannin, mepacrine, p-bromophenacyl bromaide, D-erythro-sphingosine, A23187, 
GF109203X, and forskolin (Sigma, St. Louis, MO, USA); HU210 [D8-tetrahydrocannabinol 
dimethy heptyl], AM251 [N-(piperidin-1-yl)-5-(4-indophenyl)-1-(2,4-dichlorophenyl)-4-methyl 
-1H-pyrazole-3-carboxamide], CP55940 [(-)-cis-3-[2-hydroxy-4-(1,1-domethylheptyl)phenyl]- 
trans-4-(3-hydroxypropyl) Cyclohexanol], and WIN55212-2 [R(+)-[2,3-dihydro-5-methyl-3- 
[(morpholinyl)methyl]-pyrrolo-[1,2,3-de]-1,4-benzoxazin-yl]-(1-napthalenyl)-methanone 
mesylate] (Tocris, Bristol, UK); SR141716A [N-piperidino-5-(4-chlorophenyl)-1-(2,4- 
dichlorophenyl)-4-methyl-3-pyrazole-Carboxamide] (RBI, Natick, MA, USA), ionomycin, 
PMA [4b-phorbol myristate acetate], SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl) 
-5-(4-pyridyl)-1H-imidazole], PP1 [4-amino-1-tert-butyl-3-(1’-naphthyl)pyrazolo[3,4-d] 
pyrimidine], PP2 [4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine], and PP3 
[4-amino-7-phenylpyrazol[3,4-d]pyrimidine] (a negative control for PP2), H-89 (Calbiochem, 
San Diego, CA, USA); U0126 [1,4-diamino-2,3-dicyano-1,4-bis-(o-aminophenylmercapto) 
butadiene] (Promega, Madison, WI, USA); herbimycin, tyrphostin AG1478 (Biomol. Plymouth 
Meeting, PA, USA); 2-AG [2-arachidonoyl glycerol], U73122 [1-[6[[(17b)-3-methoxyestra- 
1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione] (Cayman, Ann Arbor, MI, USA); 
pyrrophenone, and indoxam (gifts from Shionogi Ltd., Osaka, Japan), PTX (List Biol. Lab., 
Campbell, CA, USA); and CP56667 ((+)-enantiomer of CP55940, Pfizer Inc., Groton, CT, 
USA). 
 
PC12 cell culture and measurement of [3H] arachidonic acid release.  PC12 cells (Dai-Nippon 
Pharm, Osaka, Japan) were cultured on collagen-coated dishes in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 2.5% FBS and 2.5% horse serum.  The release of 
[3H]arachidonic acid was determined as previously described (Nakamura et al., 2004; Someya et 
al., 2002) with minor modifications.  Briefly, cells on dishes were cultured with 0.3 mCi/ml (11 
kBq/ml) of [3H]arachidonic acid in DMEM containing 0.2% FBS for 24 h.  The cells on dishes 
were incubated in a modified Tyrode HEPES buffer (137 mM NaCl, 5 mM KCl, 5 mM glucose, 
2 mM MgSO4, 2 mM CaCl2, 0.1% fatty acid-free albumin (Sigma), and 20 mM HEPES, pH 7.4) 
with the indicated reagents for 30 min at 37°C.  Then, the buffer was collected and centrifuged 
at 8,000 ´ g for 1 min.  Attached cells on dishes and the cell pellets were solubilized with 1% 
Triton X-100 and then [3H] content was estimated.  [3H] radioactivity released into the 
  
supernatant was expressed as a percentage of the total incorporated radioactivity 
(20,000-40,000 dpm per well).  The amounts of arachidonic acid released by stimulants were 
dependent on each experiment (1-4% of total incorporated [3H]arachidonic acid radioactivity).  
In some figures, data are presented as the fold-increase in the amount of arachidonic acid 
released or normalized as a percentage of the control response.  The viability of PC12 cells 
was estimated based on the leakage of lactate dehydrogenase (Roche, Germany).   
 
Confocal microscopy.  The plasmid for a chimeric protein containing GFP at the amino 
terminus of cPLA2a (GFP-cPLA2a) was prepared as previously described (Hirabayashi et al., 
1999).  The translocation of GFP-cPLA2a in PC12 cells was confirmed with a confocal laser 
scanning microscope (Olympus, Tokyo), as described previously (Hirabayashi et al., 1999; 
Nakamura et al., 2006). 
 
Western blotting and immunoprecipitation.  Cells harvested by scraping in PBS at 4°C were 
lysed with Triton X-100 lysis buffer (50 mM HEPES, pH 7.4, 10% glycerol, 1% Triton X-100, 4 
mM EDTA, 100 mM NaF, and 1 mM Na3VO4) containing the protease inhibitors (pepstatin, 
leupeptin, phenylmethanesulfonyl fluoride, and aprotinin) for 15 min at 4°C.  In some 
experiments, equal amounts of protein (200 mg protein in each experiment) were 
immunoprecipitated with antibodies conjugated to protein A-Sepharose for 2 h at 4°C.  
Proteins separated by SDS-PAGE were transferred to PVDF membranes and the 
immunoreactive bands were visualized using a chemiluminescent reagent (Amersham).  The 
signals of the bands were quantified with the Image Gauge software using an Image Analyzer 
LAS-1000plus (Fujifilm).  The following antibodies were used; anti-phosphotyrosine (4G10, 
Upstate, Lake Placid, NY, USA), anti-Src (Cat. No. OP07, Calbiochem), anti-Lyn (sc-15, Santa 
Cruz, CA, USA), anti-Fyn (FYN3, sc-16, Santa Cruz), anti-Yes (Cat. No. 610375, BD 
Bioscience, San Jose, CA, USA), anti-actin (clone C4, Chemicon, Temecula, CA, USA) and 
anti-cannabinoid CB1 receptor (C1233, Sigma), anti-mouse or anti-rabbit horseradish 
peroxidase-linked antibodies (Amersham, 1:1,000). 
 
In vitro Src family kinase assays.  For Src family kinase assays, the immunoprecipitates were 
washed three times in precipitation buffer and twice in TBS and split for the immunoblotting 
and kinase assay as described previously (Kasahara et al., 2004).  The immunoprecipitate was 
reacted with acid-denatured enolase in kinase buffer (50 mM HEPES, pH 7.4, 1% Triton X-100, 
10 mM MnCl2, and 1 mM Na3VO4) containing 100 mM unlabeled ATP at 30°C for the indicated 
period.  Enolase substrate was denatured in 50 mM sodium acetate at 30°C for 5 min and 
neutralized with 1 M Tris-HCl, pH 7.5.  Proteins separated by SDS-PAGE were transferred to 
  
PVDF membranes and subjected to immunoblotting with anti-phosphotyrosine antibody.   
 
Measurement of intracellular Ca2+ concentration ([Ca2+]i).  For whole cell measurements, 
PC12 cells were grown on glass bottom dishes for two days, washed with the Tyrode HEPES 
buffer, and incubated with a solution containing acetoxy-methyl (AM) ester of the fluorescent 
Ca2+ indicator (6 mM OGB-1/AM) and a dispersing reagent (pluronic acid, 0.05%) (Molecular 
Probes, Eugene, OR, USA) in the buffer for 1 h at 37°C.  Cells were washed three times with 
the buffer and then imaged in real time using an Olympus Fluoview laser scanning confocal 
microscope.  Reagents were added to the side of the dish and allowed to diffuse over the cells 
at 37°C.  Changes in [Ca2+]i were expressed as DF/F0 (= (F-F0)/F0), where F0 was the image 
obtained in the absence of stimuli.  Although DF/F0 varied depending on the cell, increases in 
[Ca2+]i were observed in 70-90% of cells. 
 
Cyclic AMP accumulation.  Cells on 60-mm dishes were treated with either vehicle or 2-AG 
for the specified period at 37°C in DMEM containing 0.1 mg/ml of isobutylmethylxanthine 
(Sigma), and then further cultured with and without 1 mM forskolin for 15 min.  The media 
were removed, 300 ml of ice-cold TE buffer (50 mM Tris-HCl, 4 mM EDTA, pH 7.5) was added, 
and the cells were scraped off and transferred to tubes.  The samples were centrifuged after 
boiling, and cyclic AMP levels in the supernatants were measured by using [3H]cyclic AMP 
(Moravek, Brea, CA, USA) and protein kinase A (Sigma, P5511), as described previously 
(Fujino et al., 2002). 
 
Mouse cerebellar cultures.  Primary dispersed cerebellar cultures were prepared from ICR 
neonatal mice as described previously (Okubo et al., 2001) with minor modifications.  The 
cerebella were treated with 1% trypsin and 0.1% DNase I in Ca2+/Mg2+-free buffer.  Dispersed 
cells were plated at a density of 3 ´ 105 cells/well on 48-well plates that had been coated with 
poly-L-lysine, and the cells were cultured in the Neurobasal medium with a 2% B-27 
supplement (GIBCO) under a humidified atmosphere containing 5% CO2.  The medium was 
changed twice a week, and cells cultured for 14-21 days were used for the AA release assay.  
By morphological analysis, granular and Purkinje cells were found to account for 60-70% and 
0.1% (100-200 cells per well) of all cells, respectively.  The other cells were non-neuronal and 
probably glial cells.  Animal experiments were performed in accordance with the Guideline 
Principles for the Care and Use of Laboratory Animals approved by the Japanese 
Pharmacological Society. 
 
cPLA2a activity in vitro.  PLA2 activity in vitro was measured using 
  
1-palmitory-2-[14C]-arachidonyl phosphatidylcholine as the substrate (Nakamura et al., 2004).  
For the measurement of activity, the cytosol fraction from human embryo kidney 293 cells 
expressing human cPLA2a was used. 
 
Data presentation.  For measurements of the release of arachidonic acid, values are the mean 
± s.e.m. for more than three independent experiments done in triplicate.  Some data show the 
mean ± s.d. for triplicate in a typical experiment, and data are representative of two or three 
independent experiments.  The significance of difference was determined using a one-way 
analysis of variance followed by Dunnett’s test.  *P values < 0.05 were considered significant. 
 
  
Results 
 
AM251-sensitive receptor- and cPLA2a-dependent release of arachidonic acid by HU210 and 
2-AG  
Stimulation of PC12 cells with 10 mM HU210 for 30 min significantly caused the 
release of arachidonic acid (Fig. 1A).  The release induced by 30 mM HU210 was 5-7-fold that 
induced by the vehicle alone, and the release induced by 3 mM HU210 was marginal.  
Stimulation with 10 and 30 mM 2-AG for 60 min released a significant amount of arachidonic 
acid, although the amount released over 30 min was much less than that over 60 min.  The 
release of arachidonic acid induced by 10 mM HU210 was almost completely inhibited by 
pretreatment of PC12 cells for 30 min with 10 and 30 mM AM251, a selective antagonist of the 
cannabinoid CB1 receptor; the fold responses were 1.0 ± 0.1 and 1.1 ± 0.1, respectively.  The 
marked release of arachidonic acid induced by 30 mM HU210 was significantly inhibited by 10 
and 30 mM AM251 (Fig. 1B).  The release by 2-AG was also inhibited by 30 mM AM251 
(Table 1).  Previously, we reported that co-treatment of PC12 cells with ceramide and 
ionomycin caused release of arachidonic acid (Nakamura et al., 2004).  The release of 
arachidonic acid induced by ceramide/ionomycin was not inhibited by 30 mM AM251, and 
AM251 by itself had no effect on the release (Fig. 1B).  Also, addition of 30 mM AM251 did 
not inhibit the cPLA2a activity in vitro (data not shown).  Treatment with 20 mM SR141716A, 
another antagonist for cannabinoid CB1 receptors, inhibited (30-40%) HU210- and 
2-AG-induced release of arachidonic acid in the present study, although we reported that the 
treatment did not inhibit 100 mM anandamide-induced release of arachidonic acid (Someya et 
al., 2002).  Treatment with HU210 or 2-AG at 10 and 30 mM was not cytotoxic for at least 60 
min after the treatment; the leakage of lactate dehydrogenase activity from cells into the 
medium was about 5-6 (% of total activity) in vehicle-, HU210- and 2-AG-treated cells.  
Stimulation of PC12 cells for 30 min with CP55940 at 10 and 30 mM released 
arachidonic acid; the fold responses were 2.0 ± 0.4 and 4.2 ± 0.5 (n = 3), respectively, and the 
responses in the 10 mM AM251-treated cells were 1.1 ± 0.2 and 1.5 ± 0.2 (n = 3), respectively.  
Treatment with 30 mM CP56667, a less active (+)-enantiomer of CP55940, did not release 
arachidonic acid (1.1 ± 0.2 fold, n = 3).  WIN55212-2 did not release arachidonic acid as 
described previously (Someya et al., 2002).  Since the release of arachidonic acid induced by 
HU210 and CP55940 was not saturated even at 100 mM, we could not estimate the EC50 values 
for the agonists.  The reasons for less effect of CP55940 and no effect of WIN55212-2 are not 
clear at present. 
Treatment with 100 mM p-bromophenacyl bromaide and 100 mM mepacrine, general 
inhibitors of PLA2, inhibited the release of arachidonic acid by HU210 (Table 1).  The tested 
  
inhibitors of secretory PLA2 such as 2 mM dithiothreitol and 10 mM indoxam had no effect on 
the amount of arachidonic acid released by 2-AG and HU210 (data not shown), although PC12 
cells endogenously express secretory PLA2s (Nabemoto et al., 2005).  We previously reported 
that D-erythro-sphingosine inhibited the release of arachidonic acid from cells and cPLA2a 
activity in vitro (Nakamura et al., 2004).  Treatment with D-erythro-sphingosine significantly 
inhibited 30 mM HU210-induced release of arachidonic acid; the values were 80.9 ± 4.9 and 
36.1 ± 2.9 (% of control, n = 3, P < 0.05) with 10 and 30 mM D-erythro-sphingosine, 
respectively.  Pyrrophenone is known to be a selective inhibitor of cPLA2a (Ono et al., 2002), 
and we confirmed that pyrrophenone at concentrations greater than 20 mM did not inhibit other 
PLA2s including the g type of cPLA2 and secretory PLA2s.  Pyrrophenone from 0.2 mM 
inhibited the HU210-induced release of arachidonic acid, and at 10 mM almost completely 
inhibited the release (Fig. 1C and Table 1).  Pretreatment with 10 mM pyrrophenone markedly 
and significantly inhibited the 2-AG-induced release of arachidonic acid for 60 min (Table 1). 
Stimulation with a Ca2+ ionophore triggered the translocation of a chimeric protein 
(GFP-cPLA2a) from the cytosol to the perinuclear region within 1-2 min in cells (Hirabayashi 
et al., 1999; Shimizu et al., 2004).  In PC12 cells, 5 mM ionomycin triggered the translocation 
of GFP-cPLA2a within 1 min (Fig. 2, Upper panels).  The translocation induced by ionomycin 
was retained for over 10-20 min, and then reversed within 1 h.  Treatment with 30 mM HU210 
caused the translocation of GFP-cPLA2a to the perinuclear region within 10 min after the 
treatment (Fig. 2, Middle panels).  The translocation induced by 30 mM HU210 was transient 
and reversed within about 1 h.  Treatment with 10 mM HU210 caused the translocation, 
although the response was weaker than that by 30 mM HU210.  Pretreatment with 30 mM 
AM251 inhibited the effect of HU210, but not 5 mM ionomycin (data not shown).  Treatment 
with 10 mM 2-AG also caused the translocation of GFP-cPLA2a within 7-15 min (Fig. 2, 
Lower panels).  In the absence of extracellular CaCl2, the translocation induced by ionomycin 
did not occur, and the response by HU210 was detected in some cells (data not shown).  In 
contrast to GFP-cPLA2a, unconjugated GFP was distributed homogeneously in the cytosol and 
nucleus, and its distribution was not affected by ionomycin, HU210, and 2-AG (data not 
shown).   
 
HU210-induced tyrosine phosphorylation and activation of Src, Fyn, and Yes 
Activation of cannabinoid CB1 receptors in neurons activates tyrosine kinases such as 
Src and Fyn (Derkinderen et al., 2001; He et al., 2005; Howlett, 2004) and the phospholipase C 
(PLC) pathway (Demuth and Molleman, 2006; Lauckner et al., 2005).  The release of 
arachidonic acid induced by HU210 was significantly inhibited by 1 mM herbimycin (a general 
inhibitor of tyrosine kinases) and by 10 mM PP1 and 10 mM PP2 (selective inhibitors of Src 
  
family kinases) (Table 1).  The response induced by 2-AG was inhibited by PP2.  The 
inhibitors alone had no effect on the release, and treatment with PP3 at 20 mM, a negative 
control for PP2, did not inhibit the release by 2-AG (Table 1) and by HU210 (data not shown).  
These findings suggest the potential involvement of the Src family kinases in the 
cannabinoids-induced release of arachidonic acid.  In the subsequent experiments, PC12 cells 
were stimulated with HU210 since the responses (release of arachidonic acid and translocation 
of cPLA2a) were faster and greater than those to 2-AG.  Treatment with 30 mM HU210 
increased the tyrosine phosphorylation of a number of proteins in PC12 cells (Fig. 3A).  The 
increase was detected 5 min after the treatment, and continued for 30 min.  Two bands at ~ 60 
kDa (58 and 60 kDa) were detected in HU210-treated cells with the anti-phosphotyrosine 
antibody (Fig. 3B).  The membrane was well washed and reprobed with the respective 
antibody.  The lower band (58 kDa) was the band cross-reacted with anti-Src and anti-Fyn 
antibody, and the upper band (60 kDa) consisted with the anti-Yes antibody-reacted band.  The 
estimated sizes of Src, Fyn, and Yes were 60, 59, and 62 kDa, respectively.  The estimated 
sizes of Lyn are 53 and 56 kDa, and the bands that cross-reacted with anti-Lyn antibody in PC12 
cells were not consistent with the bands that cross-reacted with the anti-phosphotyrosine 
antibody.  To identify these proteins, Src, Fyn, and Yes were isolated by immunoprecipitation 
with the respective antibody and tested for tyrosine phosphorylation (Fig. 3C).  Src, Fyn, and 
Yes were tyrosine phosphorylated by the HU210 treatment.  Pretreatment with 10 mM PP2 
markedly decreased the tyrosine phosphorylation of most proteins in vehicle-treated cells, and 
the tyrosine phosphorylation of proteins including Src, Fyn, and Yes induced by HU210 (data 
not shown).  To fully address the issue of HU210’s regulation of the Src family kinases, kinase 
activity was measured by using enolase as a substrate.  Immunoprecipitated preparations 
obtained from HU210-treated PC12 cells with anti-Src antibody (Fig. 4A) and anti-Fyn 
antibody (Fig. 4B) showed increased activities of tyrosine kinases.  The levels of tyrosine 
phosphorylation of enolase relative to the amounts of Src or Fyn at 30 min after stimulation 
were quantified; the responses in Src and Fyn were increased 3.8 ± 1.1-fold and 2.9 ± 0.7-fold, 
respectively (n = 3, P < 0.05).  In preliminary experiments, treatment with 100 ng/ml pertussis 
toxin (an inhibitor of Gi/o proteins) did not affect the tyrosine phosphorylation of Src by HU210 
(data not shown). 
 
Signaling pathways in release of arachidonic acid induced by 2-AG and HU210 
Treatment with the indicated concentrations of U73122, an inhibitor of PLC, 
significantly reduced the amount of arachidonic acid released by 10 mM 2-AG (Fig. 5A).  
Activation of the PLC pathway in cells leads to the activation of the protein kinase C (PKC) 
pathway and an increase in [Ca2+]i levels.  Treatment with 10 mM GF109203X, an inhibitor of 
  
PKC, markedly (50-80%) inhibited the release of arachidonic acid by 10 mM 2-AG for 1 h and 
by 30 mM HU210 for 30 min (Fig. 5B).  Treatment with 100 nM PMA (an activator of PKC) 
plus 10 mM A23187 (a Ca2+ ionophore) stimulated the release of arachidonic acid for 30 min; 
the values (% of total) were 1.5-2% and 5-7% in the control and PMA/A23187-treated cells, 
respectively.  The response induced by PMA/A23187 was markedly inhibited by treatment 
with 10 mM GF109203X.  By contrast, treatment with U73122 did not inhibit the release of 
arachidonic acid by PMA/A23187; the values were 6.1 ± 0.3% and 6.1 ± 0.4% (mean ± s.d.) in 
the control and the 10 mM U73122-treated cells, respectively, in a typical experiment.  The 
response to PMA/A23187 was not inhibited by 10 mM PP2 (data not shown). 
Next, we investigated the changes in [Ca2+]i in PC12 cells by using a fluorescent Ca2+ 
indicator (Fig. 6).  Pictures on the left show typical images before and after stimulation, and 
figures on the right show the time-course of changes in [Ca2+]i in one or two selected cells.  
Treatment with 10 mM ionomycin rapidly caused an increase in [Ca2+]i within 1 min in the 
presence of extracellular CaCl2.  Treatment with 30 mM HU210 and 10 mM 2-AG also caused 
an increase in [Ca2+]i; the responses increased about 1-2 min after the treatment, and then 
returned to the baseline at 30-60 min.  The time-course and intensity of the responses varied 
with each experiment, but the order of maximal response by stimulants was 10 mM ionomycin > 
30 mM HU210 > 10 mM 2-AG.  Pretreatment with 10 mM U73122 for 30 min abolished the 
increase in [Ca2+]i induced by 2-AG, however, it had no effect on the ionomycin-induced 
response.  Pretreatment with 10 mM PP2 for 30 min abolished or reduced the response evoked 
by 2-AG (Fig. 6, bottom Panel), but not by ionomycin (data not shown).  Treatment with 100 
ng/ml pertussis toxin did not affect the changes in [Ca2+]i by 2-AG and HU210 (data not shown).  
These findings suggest that stimulation with 2-AG and HU210 appears to activate the 
Src-pathway and consequently the PLC pathway leading to an increase in [Ca2+]i in PC12 cells.   
We examined the effects of several inhibitors of other signaling molecules on release 
of arachidonic acid by HU210; U0126 and PD098059 (both 10 mM, ERK1/2 kinase inhibitors), 
SB203580 (10 mM, p38 kinase inhibitor), and wortmannin (3 mM, phosphatidylinositide 
3-kinase inhibitor).  However, pretreatment with the inhibitors did not change the amount of 
arachidonic acid released by HU210.  For instance, 30 mM HU210-induced release was 8.9 ± 
0.6% (mean ± s.d., % of total) in control, 8.7 ± 0.2% in U0126-treated, 9.4 ± 0.1% in 
PD098059-treated, 8.6 ± 0.8% in SB203580-treated, and 7.6 ± 0.3% in wortmannin-treated cells, 
in a typical experiment.  The basal release of arachidonic acid without HU210 in control cells 
was 2.2 ± 0.1%, and the values in the inhibitor alone-treated cells were 2.0-2.5 ± 0.1%.  
Treatment with an inhibitor of c-Jun N-terminal kinase (SP600125, 10 mM) did not inhibit the 
release of arachidonic acid by 30 mM HU210 (data not shown).  The release induced by 2-AG 
for 60 min was not changed by these inhibitors.  EGF alone had no effect and did not enhance 
  
the Ca2+ ionophore-induced release of arachidonic acid (data not shown).  The amount of 
arachidonic acid released by 10 mM 2-AG was not changed by 1 and 10 mM AG1478, a 
selective inhibitor of the tyrosine kinase of EGF receptors, the value (% of total) being 2% in 
the control cells, ~ 8% in the 2-AG-treated cells, and ~ 8% in the AG1478 plus 2-AG-treated 
cells.   
 
Abolishment of 2-AG-induced cyclic AMP response but not release of arachidonic acid by 
pertussis toxin pretreatment 
Treatment of PC12 cells with 100 ng/ml of pertussis toxin did not affect the amount of 
arachidonic acid released by 2-AG (Fig. 7A) and by HU210 (data not shown).  Treatment with 
10 mM 2-AG inhibited the forskolin-stimulated accumulation of cyclic AMP in PC12 cells (Fig. 
7B), and the cyclic AMP response induced by 2-AG was mediated by AM251-sensitive 
cannabinoid receptors (Fig. 7C).  The inhibition of cyclic AMP accumulation induced by 2-AG 
was almost completely inhibited by pertussis toxin treatment (Fig. 7B). 
 
2-AG-induced release of arachidonic acid in cultured cells from mouse cerebellum 
The existence of cannabinoid CB1 receptors is shown in the granular layers and 
Purkinje cells from neonatal and adult mouse cerebellum (Bayatti et al., 2005; Kawamura et al., 
2006).  The stimulation of primary cultured cells from the cerebellum with 1 and 10 mM 2-AG 
caused the release of arachidonic acid within 15 min (Fig. 8A).  Treatment with 30 mM AM251 
and 10 mM pyrrophenone largely inhibited the release induced by 10 mM 2-AG (Fig. 8B).  
Like in PC12 cells, the 2-AG-induced release of arachidonic acid was inhibited by PP2 and 
U73122 in the cerebeller cells.   
 
  
Discussion 
 
Role of cPLA2a in 2-AG- and HU210-induced release of arachidonic acid 
In this study, treatment with 2-AG and HU210 with greater concentrations than 3 mM 
caused the release of arachidonic acid and translocation of cPLA2a in PC12 cells.  2-AG is 
directly metabolized to arachidonic acid by lipase and amidohydrolase (Bisogno et al., 1998; 
Piomelli, 2003), but our data suggest the role of cPLA2a in the release of arachidonic acid 
induced by 2-AG and HU210 in PC12 cells.  The amount of arachidonic acid released by 
2-AG was markedly reduced by general inhibitors of PLA2 such as p-bromophenacyl bromaide, 
and was almost completely inhibited by a selective inhibitor of cPLA2a (pyrrophenone).  The 
intracellular translocation of cPLA2a is regulated by Ca2+ (Hirabayashi et al., 1999; Leslie, 
1997).  Like the Ca2+ ionophore, 2-AG and HU210 caused an increase in [Ca2+]i (Fig. 6) and 
the translocation of cPLA2a (Fig. 2) in PC12 cells.  Thus, both the 2-AG- and HU210-induced 
release of arachidonic acid is likely to be mediated by cPLA2a activation in PC12 cells.   
 
Role of Src family kinases in a pertussis toxin-insensitive manner on release of arachidonic 
acid 
The stimulation of neuronal cells with cannabinoids and/or agonists for cannabinoid 
receptors activates the Src family kinases including Src and Fyn, which in turn phosphorylate 
multiple substrates (Davis et al., 2003; Derkinderen et al., 2001; Derkinderen et al., 2003; He et 
al., 2005).  We showed that stimulation of PC12 cells with HU210 increased tyrosine 
phosphorylation of Src, Fyn, and Yes, and the tyrosine kinase activities of Src and Fyn (Figs. 3, 
4).  Since the amount of arachidonic acid released by HU210 was markedly decreased by 
inhibitors of tyrosine kinases, activation of Src family kinases or at the very least, Src and Fyn, 
is involved in the HU210-induced release of arachidonic acid from PC12 cells.  Under our 
conditions, the transactivation of EGF receptors induced by G protein-coupled receptors 
including cannabinoid receptors (Hart et al., 2004) was excluded.  
It is reported that the stimulation of cannabinoid CB1 receptors activated tyrosine 
kinases including Src via pertussis toxin-sensitive Gi/o proteins in rat hippocampal slices 
(Derkinderen et al., 2001) and in neuro-2A cells (He et al., 2005).  In PC12 cells, pertussis 
toxin-sensitive G proteins are involved in the inhibition of cyclic AMP formation (Fig. 7 B), but 
not in the release of arachidonic acid (and activation of Src family kinases), induced by 2-AG.  
Pertussis toxin did not affect the D9-tetrahydrocannabinol-induced release of arachidonic acid 
from rat hippocampal neurons (Chan et al., 1998), and cellular responses mediated by 
cannabinoid CB1 receptors in certain cells were pertussis toxin-insensitive (Guo et al., 2004; 
Rubovitch et al., 2002).  Cannabinoid CB1 receptors could interact with pertussis 
  
toxin-insensitive G proteins such as Gs and G12/13 in neuroblastoma cells (Ishii and Chun, 2002), 
and with Gq/11 leading to activation of the PLC pathway in mouse hippocampal neurons 
(Lauckner et al., 2005).  These reports and our findings suggest the existence of a G 
protein-independent pathway and/or role of pertussis toxin-insensitive G proteins in the 
activation of Src family kinases and the resulting release of arachidonic acid induced by 2-AG 
and HU210 in PC12 cells.  
In several neuronal cells, the activation of cannabinoid CB1 receptors inhibits 
production of cyclic AMP followed by stimulation of intracellular signaling pathways such as 
the activation of tyrosine kinases and ERK1/2 (Davis et al., 2003; Derkinderen et al., 2001; 
Derkinderen et al., 2003).  Under our conditions, treatment with pertussis toxin abolished the 
cyclic AMP response but not the activation of Src and release of arachidonic acid induced by 
2-AG or HU210 in PC12 cells.  By contrast, phosphorylation of Src at Ser17 within the amino 
terminus by a cyclic AMP-dependent protein kinase is known to activate Src in PC12 cells 
(Obara et al., 2004).  2-AG did not stimulate cAMP accumulation in PC12 cells (Fig. 7).  
Treatment with 5 mM forskolin by itself did not stimulate the release of arachidonic acid, and 
treatment with 10 mM H-89 (an inhibitor of the cyclic AMP-dependent protein kinase) did not 
change the release for 60 min in the presence or absence of 10 mM 2-AG (data not shown).  
Thus, cyclic AMP-related events are not likely to contribute to the release of arachidonic acid 
induced by 2-AG in PC12 cells. 
 
Roles of the PLC and PKC pathways 
Not only U73122, but also PP2 pretreatment decreased the 2-AG-induced [Ca2+]i 
response in PC12 (Fig. 6).  In preliminary experiments, U73122 had no effect on the tyrosine 
phosphorylation of Src induced by HU210 (data not shown).  The release of arachidonic acid 
by 2-AG and HU210 was inhibited by PP2, U73122 and GF109203X.  On the other hand, the 
release by PMA/A23187 was inhibited by GF109203X, but not by U73122.  Thus, it is likely 
that the Src pathway lies upstream of the PLC pathway, and the PKC pathway exists 
downstream of the PLC pathway.  Our data suggest that stimulation with 2-AG and HU210 
activates the Src family kinases followed by activation of the PLC pathway, and then the PKC 
pathway in cooperation with Ca2+ couples cPLA2a activation in PC12 cells (Fig. 9). 
It has been established that the ERK1/2 pathway lies downstream of the PKC pathway, 
and has a role in the activation of cPLA2a in various cells (Hirabayashi et al., 1999; Leslie, 
1997).  In fibroblasts, anandamide-induced cPLA2a activation was dependent on the ERK 
pathway (Wartmann et al., 1995).  In the present study, however, treatment with two different 
inhibitors of ERK1/2 kinase did not reduce the amount of arachidonic acid released by HU210 
in PC12 cells.  Since treatment with 10 mM U0126 completely abolished the phosphorylation 
  
of ERK1/2 (data not shown) and caused a marked inhibition in the release of arachidonic acid 
by PMA/A23187, the ERK pathway appeared to regulate the release of arachidonic acid 
induced by PMA, but not by HU210.  Thus, activation of cPLA2a induced by HU210 and 
2-AG in PC12 cells is likely to be PKC-dependent and ERK1/2-independent.  It is reported 
that the stimulation of G protein-coupled receptors caused the activation of cPLA2 and/or 
release of arachidonic acid in a PKC-dependent and an ERK-independent manner in human 
embryonic kidney 293 cells expressing the Ca2+-sensing receptor (Handlogen et al., 2001) and 
in murine astrocytes expressing endogenously the P2Y receptor (Xu et al., 2002).  Further 
studies are required to elucidate the precise mechanism that lies downstream of the PKC 
pathway and regulates the activity of cPLA2a in PC12 cells. 
 
Possible involvement of AM251-sensitive receptors in cannabinoid-induced response 
Under our conditions, 2-AG and HU210 at greater concentrations than 3 mM caused 
the responses such as activation of Src family kinases and release of arachidonic acid.  Several 
reports showed that agonist of cannabinoid receptor greater than 3 mM caused cannabinoid CB1 
receptor-mediated cellular responses (Facchnetti et al., 2003; Oshita et al., 2005).  The low 
efficacy and potency of 2-AG and HU210 in PC12 cells may be due to the relative paucity of or 
the amount of active form of cannabinoid CB1 receptors in cells.  The existence of cannabinoid 
CB1 receptor in PC12 cells were reported (Sarker and Maruyama, 2003), although another 
report suggested that PC12 cells are not endowed with cannabinoid CB1 receptors (Molderings 
et al., 2002).  Recently, Zhang et al. (2007) reported the expression of both cannabinoid CB1 
receptor mRNA and protein in PC12 cells and their changes induced by high glucose 
concentrations in medium.  A trace amount of cannabinoid CB1 receptor-immunoreactivity (~ 
65 kDa) was detected in PC12 cells used in this study (data not shown).  The amount of 
endogenous receptors including cannabinoid CB1 receptors may be dependent on sub-clones of 
PC12 cells.  Cannabinoid CB1 receptors may exist in several active states (Lauckner et al., 
2005), and the alteration of experimental conditions allows the constitutive activity and/or 
desensitization of cannabinoid CB1 receptors (Howlett, 2004; Kouznetsiva et al., 2002).  Since 
PC12 cells can produce 2-AG and anandamide (Bisogno et al., 1998), a change in the active 
state of cannabinoid CB1 receptors in PC12 cells is probable.  The binding affinity and the 
signaling of cannabinoid CB1 receptors varied by receptor modification such as N-glycosylation 
and phosphorylation (Demuth and Molleman, 2006; Lutz, 2002).  It is reported that 
cannabinoid CB1 receptors function within lipid rafts plasma membrane microdomains, and 
lipid rafts can modulate binding and signaling of cannabinoid CB1 receptors (Bari et al., 2005).  
Also, a splice variant of the cannabinoid CB1 receptor (CB1A receptor) was cloned (Shire et al., 
1995).  In the present study, treatment with AM251 inhibited the responses (increase in [Ca2+]i, 
  
translocation of cPLA2a and the release of arachidonic acid) induced by 2-AG and HU210, and 
another antagonist of cannabinoid CB1 receptor (SR141716A) inhibited HU210-induced release 
of arachidonic acid, although the greater concentrations were required for the inhibition.  The 
release of arachidonic acid induced by 30 mM HU210 was largely (~ 80%) inhibited by 30 mM 
AM251 (Fig. 1B), but the response by 100 mM HU210 was partially (~ 50%) inhibited by the 
antagonist (data not shown).  Since we could not estimate EC50 values of the HU210- and 
CP55940-induced release of arachidonic acid, we could not estimate the optimal concentration 
of AM251.  Treatment with CP55940, but not its (+) enantiomer CP56667, stimulated release 
of arachidonic acid in PC12 cells.  Thus, the 2-AG- and HU210-induced responses appear to 
be mediated by surface expressing receptor(s) such as cannabinoid CB1 and/or CB1-like 
receptors. 
However, we could not role out the possibility of involvement of some selective 
molecules and/or pathways besides the receptor(s) that are sensitive to AM251.  Molderings et 
al. (2002) suggest the existence of noradrenaline release-inhibiting receptors that were activated 
by cannabinoid agonists with low potency activation and were inhibited by antagonists of 
cannabinoid CB1 receptor in PC12 cells.  In addition, there are several reports showing the 
cannabinoid CB1 receptor-independent effects of cannabinoids in PC12 cells (Erlandsson et al., 
2002; Esposito et al., 2006; Sarker et al., 2003).  Studies using cannabinoid CB1 and CB2 
receptor knockout mice indicated that some effects of cannabinoids are mediated neither by 
cannabinoid CB1 nor CB2 receptors, pointing to the existence of additional as-yet-unidentified 
sites and/or receptors (Begg et al., 2005; Hájos et al., 2001; Demuth and Molleman, 2006; 
Nilsson et al., 2006).  Recently, GPR55 was established to be a novel cannabinoid receptor that 
has unique pharmacological properties (Lauckner et al., 2007; Ryberg et al., 2007).  
Identification of cannabinoid receptors involved in the observed HU210-induces responses in 
PC12 cells remained to be solved.  Previously, we reported that anandamide stimulated release 
of arachidonic acid from PC12 cells, and the response was cannabinoid receptor-independent 
(Someya et al., 2002).  2-AG and HU210 are full efficacy agonists, more potent than 
anandamide, in mediating cannabinoid receptor-mediated signaling (Howlett, 2004; Savinainen 
et al., 2001).  It is possible that the signaling for anandamide-induced release of arachidonic 
acid may be different from the signaling evoked by 2-AG and HU210. 
Some of cannabinoid receptor-independent effects induced by cannabinoids may be 
derived from the antioxidant properties and their high degree of lipophilicity of ligands (Begg et 
al., 2005; Demuth and Molleman, 2006).  Although treatment with 2-AG at 20 mM did not 
cause the cell death within 24 h (Sarker and Maruyama, 2003), some cannabinoids can cause the 
death of PC12 cells (Erlandsson et al., 2002; Sarker and Maruyama, 2003).  In the present 
study, neither 2-AG nor HU210 at the used concentrations showed cell toxicity, and marked 
  
morphological changes such as membrane ruffling were not observed under the confocal 
microscope (translocation of cPLA2a and [Ca2+]i measurement) by the reagents.  The 
responses induced by 2-AG and HU210 were decreased by treatment with several inhibitors of 
intracellular signaling and/or enzymes such as PP2 and pyrrophenone.  A possibility of 
non-specific physico-chemical effects induced by 2-AG and HU210 may be excluded. 
A proposed mechanism for the 2-AG- and HU210-induced release of arachidonic acid 
is shown in Fig. 9.  It is likely that the cannabinoids stimulate AM251-sensitive cannabinoid 
CB1 and/or CB1-like receptors, and increase the activities of Src family tyrosine kinases (Src, 
Fyn and Yes) resulting in the activation of PLC in a pertussis toxin-insensitive manner in PC12 
cells.  The activation of PLC diverges into two signals, an increase in [Ca2+]i and 
phosphorylation signal that is mediated by the PKC pathway.  Those signals cause the 
intracellular translocation and activation of cPLA2a, respectively.  Treatment with 2-AG 
caused the release of arachidonic acid from primary cultured cells from mouse cerebellum via 
similar mechanisms with cPLA2a activation.  Our findings show a possible mechanism of 
release of arachidonic acid induced by cannabinoids.  Neuroprotective effects of cannabinoids 
in the nervous system are proposed, and the loss of cannabinoid CB1 receptors has been 
demonstrated in a number of neurodegenerative diseases (Bahr et al., 2006; Glass et al., 2004).  
The protein level of cannabinoid CB1 receptors appears to be down-regulated in PC12 cells 
grown in conditions mimicking hyperglycemia and in neurons from diabetic rats (Zhang et al., 
2007).  The precise interaction between cannabinoid-related changes and arachidonic acid 
metabolism in neuronal cells should be solved in future.  In addition, more direct evidence is 
still needed in order to show that HU210-induced responses are mediated via a 
receptor-mechanism. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.  Release of arachidonic acid induced by HU210 and 2-AG in PC12 cells.  In Panel A, 
labeled cells were incubated with the indicated concentrations of HU210 for 30 min or 2-AG for 
1 h. Data are presented as the fold-increase in the amount of arachidonic acid released.  In 
Panel B, the cells were incubated with vehicle or 10 and 30 mM AM251 for 30 min, and then 
further incubated for 30 min with 30 mM HU210 (open column) or vehicle (hatched column). In 
Panels A and B, data are means ± s.e.m. for 3–4 independent experiments.  *P < 0.05, 
significantly different from the control.  In Panel C, the cells were incubated with the indicated 
concentrations of pyrrophenone for 30 min, and then further incubated for 30 min with 30 mM 
HU210 (open column) or vehicle (hatched column). Data in Panel C are means ± s.d. for 
triplicate from a typical experiment of two independent experiments.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  Translocation of cPLA2a induced by HU210 and 2-AG.  PC12 cells were transfected 
with the expression vector encoding GFP-human cPLA2a. Pictures on the left and the right 
show before and after stimulation, respectively.  Cells were stimulated with 5 mM ionomycin 
for 1 min (Upper), 30 mM HU210 for 10 min (Middle), and 10 mM 2-AG for 10 min (Lower). 
Vehicle did not affect the location of GFP-human cPLA2a in cells at least for 15 min.  Data are 
from an experiment typical of three independent experiments.  Scale bar, 10 mm.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.  Tyrosine phosphorylation of proteins in PC12 cells induced by HU210.  In Panel A, 
PC12 cells were incubated with 30 mM HU210 for the period indicated.  Total cell lysate was 
analyzed by Western blotting with anti-phosphotyrosine (anti-PY) antibody and/or anti-b-actin 
antibody.  In Panel B, samples fromcells stimulated with or without 30 mM HU210 for 30 min 
were fractionated by SDS-PAGE for a longer period to separate ~60 kDa proteinbands.  
Tyrosine phosphorylation was determined by probing with anti-phosphotyrosine antibody, and 
the bandswere analyzed by subsequent reprobingwith anti-Src, anti-Fyn, anti-Yes, and anti-Lyn 
antibodies.  In Panel C, samples from vehicle-treated cells (lanes 1, 3 and 5) and 
HU210-treated cells (lanes 2, 4 and 6) were immunoprecipitated with anti-Src, anti-Fyn, and 
anti-Yes antibodies, and then analyzed by Western blotting with anti-phosphotyrosine antibody. 
Data are from an experiment typical of two independent experiments. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.  Tyrosine kinase activities of Src and Fyn in HU210-treated cells.  PC12 cells were 
stimulated with 30 mM HU210 for the period indicated (Panel A) or for 30 min (Panel B). 
Immunoprecipitates obtained with anti-Src antibody (Panel A) and anti-Fyn antibody (Panel B) 
were subjected to in vitro kinase assays with or without 100 mM ATP. Kinase reactions were 
determined by probing with anti-phosphotyrosine (anti-PY) antibody, and Src and Fyn 
immunoprecipitateswere analyzed by subsequent reprobing with the respective antibody.  Data 
are from an experiment typical of three independent experiments.
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5  Effects of U73122 and GF109203X on the release of arachidonic acid induced by 2-AG 
and HU210.  Labeled PC12 cells were incubated with the indicated concentrations of U73122 
(Panel A) and 10 mM GF109203X (Panel B) for 30 min, and then stimulated with cannabinoids.   
In Panel A, the cells were stimulated for 1 h with 10 mM 2-AG (open column) or vehicle 
(hatched column). Data are presented as the fold-increase in the amount of arachidonic acid 
released, and are means ± s.e.m. for three independent experiments.  *P < 0.05, significantly 
different from the control without U73122.  In Panel B, the control cells (open column) and 
GF109203X-treated cells (hatched column) were stimulated with 10 mM 2-AG for 1 h, 30 mM 
HU210 for 30 min, and 100 nM PMA plus 10 mM A23187 for 30 min.  Net increases in the 
release by stimuli are normalized as a percentage of the control.  Data in Panel B are means ± 
s.d. for triplicate from a typical experiment of two independent experiments.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.  2-AG- and HU210-induced increases in [Ca2+]i and inhibitory effects of U73122 and 
PP2 pretreatment.  PC12 cells were incubated with 6 mM OGB-1/AM for 1 h.  The 
time-course of changes in DF/F0 in one or two typical cells is shown on the right.  Typical 
images before and after stimulation are shownon the left (10 mM ionomycin for 1min, 30 mM 
HU210 for 2min, and 10 mM 2-AG for 2min).  In some cases, the cells were pretreated with 10 
mM U73122 or with 10 mM PP2 for 30min, and then stimulated with 10 mM 2-AG for the period 
indicated.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7.  Effect of pertussis toxin on the release of arachidonic acid and on inhibition of cyclic 
AMP formation induced by 2-AG.  In Panel A, PC12 cells were labeled for 24 h with 
[3H]arachidonic acid in the presence (●) and absence (○) of 100 ng/ml of pertussis toxin 
(PTX). The total incorporated radioactivity in the pertussis toxintreated cells was almost same 
as that in the control (30,000–40,000 dpm per well).  The cells were incubated with the 
indicated concentrations of 2-AG for 1 h.  Data are means ± s.e.m. for 3-4 independent 
experiments.  *P < 0.05, significantly different from the control without 2-AG treatment.  In 
Panel B, cells were cultured with vehicle (○●) or 100 ng/ml pertussis toxin (△▲) for 18 h, 
and then incubated with 10 mM 2-AG for the period indicated. The cells were stimulated with 1 
mM forskolin for 15 min (●▲) and the amount of cyclic AMP formed was measured.  The 
level of cyclic AMP in cells not stimulated with forskolin was low and not affected by 2-AG 
treatment (○△).  In Panel C, cells were cultured with vehicle or 30 mM AM251 for 30 min, 
and then further incubated with or without 10 mM 2-AG for 60 min.  The amount of cyclic 
AMP formed was measured 15 min after treatment with 1 mM forskolin.  In Panels B and C, 
data are means ± s.d. for triplicate from a typical experiment of two independent experiments.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8.  Arachidonic acid released by 2-AG inprimary cultured cells frommouse cerebellum.  
Cerebellar cultures were labeled with [3H]arachidonic acid for 24 h.  In panel A, the washed 
cells were stimulated with vehicle (○), 1 mM 2-AG (●), and 10 mM 2-AG(▲) for 15 and 30 
min.  In Panel B, the cells were incubated with the indicated inhibitors for 30 min, and then 
further incubated with 10 mM 2-AG for 30 min.  The inhibitors used were 10 mM AM251, 5 
mM pyrrophenone, 10 mM PP2 and 3 mM U73122.  Data are means ± s.d. for triplicate from a 
typical experiment of two independent experiments.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9.  Signaling mechanism of release of arachidonic acid induced by 2-AG and HU210 in 
PC12 cells.  Treatment with 2-AG or HU210 stimulates AM251-sensitive cannabinoid CB1 
and/or CB1-like receptors in PC12 cells.  Inhibition of Gi/Go functions by pertussis toxin (PTX) 
treatment abolished the cyclic AMP response (an inhibition of cyclic AMP formation) but did 
not inhibit the release of arachidonic acid induced by cannabinoid ligands.  Treatment with 
HU210 stimulated tyrosine phosphorylation as well as tyrosine kinase activities of Src, Fyn and 
Yes, that resulted in PLC activation. Activation of cPLA2a (translocation induced by Ca2+ and 
phosphorylation induced by the PKC-dependent pathway) resulted in the release of arachidonic 
acid from neuronal cells. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Effects of inhibitors of cannabinoid receptor, cPLA2a, and Src family kinases.  
Labeled PC12 cells were incubated with the indicated inhibitors for 30 min, and then further 
incubated with 30 mM HU210 for 30 min (Exp. I) or 10 mM 2-AG for 60 min (Exp. II).  Net 
increases in the amount of arachidonic acid released by HU210 or 2-AG are normalized as a 
percentage of the control. Data are means ± s.e.m. for the indicated number (n) of independent 
experiments, and some data in Exp. II are from two independent experiments.  *P < 0.05, 
significantly different from the control with vehicle. 
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Concluding Remarks 
 
In Chapter I, simultaneous treatment of AMPA and PMA, a chemical method of 
inducing LTD, caused full activation of cPLA2a: translocation and phosphorylation, in cultured 
Purkinje cells.  When Purkinje cells were treated with glutamate or AMPA, cPLA2a 
translocated from cytosol to Golgi complex in somatic and dendritic regions.  This 
translocation required Ca2+ influx through P type Ca2+ channels because EGTA or w-agatoxin 
IVA blocked the translocation.  Activation of mGlu receptors didn’t induce the cPLA2a 
translocation.  Immunocytochemical analysis showed that cPLA2a was phosphorylated on 
Ser505 by simultaneous stimulation with AMPA and PMA but not by glutamate or AMPA alone.  
Because pretreatment with pyrrophenone blocked the prolonged loss of the receptor from the 
surface at 2 h after PMA and AMPA treatment without changing the decrease of the receptor 
during the initial 10 min, full activation of cPLA2a was required by long-term sustainment of 
AMPA receptors internalization.  
In Chapter II, treatment with 2-AG and HU210 resulted in the release of arachidonic 
acid, and the response was inhibited by AM251 and by pyrrophenone in PC12 cells.  The 
cannabinoid treatment caused the intracellular translocation of cPLA2a and an increase in the 
intracellular Ca2+ level.  Treatment with HU210 caused tyrosine phosphorylation of Src and 
Fyn, and increased their kinase activities.  Pretreatment with inhibitors of tyrosine kinases or 
PLC abolished the cannabinoids-induced release of arachidonic acid and Ca2+ response, and 
PKC inhibitor reduced the release of arachidonic acid.  2-AG caused the release of arachidonic 
acid from cultured cells of the mouse cerebellum via similar mechanisms.  These data reveal 
that cannabinoids activated cPLA2a in a Src-PLC-PKC-dependent manner probably via 
cannabinoid CB1 receptor and/or CB1-like receptor in neuronal cells.  
In the CNS, cPLA2a is predominantly expressed in neuronal cells and affect brain 
function at physiological and pathological situations.  We success to investigate the detail 
mechanism for the activation in neuronal cells including Purkinje cells and PC12 cells.  Our 
study found that cPLA2a activity can be regulated by activation of distinct neurotransmitter 
receptors and subsequentally cellular signalings.  We believe that elucidation of the activation 
mechanism of cPLA2a in neuronal cells lead to gain clinical benefits such as inhibition of 
neuronal death during brain ischemia and to understand process of memory formation and 
learning.   
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